image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
d3104e77f38897d5014b9c292e88d01f098c02e10c26d9bcde1472a35a660c3b.png | complex | <table><tr><td></td><td></td><td>Before pregnancy</td><td>1st trimester</td><td>2nd trimester</td><td>3rd trimester</td><td>6 months post-partum</td></tr><tr><td>Mean sexual frequency for all respondents</td><td></td><td>1.8</td><td>1.2</td><td>1.4</td><td>1.35</td><td>1.36</td></tr><tr><td rowspan="2">Circumcised females</td><td>Yes</td><td>1.8*</td><td>1.1*</td><td>1.3</td><td>1.3</td><td>1.2*</td></tr><tr><td>No</td><td>2.1</td><td>1.4</td><td>1.5</td><td>1.4</td><td>1.6</td></tr><tr><td rowspan="2">Episiotomy performed at delivery</td><td>Yes</td><td>—</td><td>—</td><td>—</td><td>—</td><td>1.3</td></tr><tr><td>No</td><td>—</td><td>—</td><td>—</td><td>—</td><td>1.2</td></tr><tr><td rowspan="2">Mode of delivery</td><td>Vaginal</td><td>—</td><td>—</td><td>—</td><td>—</td><td>1.2**</td></tr><tr><td>Caesarean section</td><td>—</td><td>—</td><td>—</td><td>—</td><td>2.3</td></tr><tr><td rowspan="2">Partners said to be engaged in extramarital affairs</td><td>Yes</td><td>1.5</td><td>1.1</td><td>1.0*</td><td>0.9*</td><td>1.2</td></tr><tr><td>No</td><td>1.9</td><td>1.2</td><td>1.5</td><td>1.4</td><td>1.4</td></tr></table> |
5d42b2e95ed90ca09a0c88c05f6919d15ff109ad4fd0df462aa08a7e9df0a5e9.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">Control Group</td><td colspan="3">Intervention Group</td></tr><tr><td colspan="3">N=51</td><td colspan="3">N=51</td></tr><tr><td>Study period</td><td>6 m (i)</td><td>6 m (f)</td><td>Final</td><td>6 m (i)</td><td>6 m (f)</td><td>Final</td></tr><tr><td>Length of time (mean [SD], days)</td><td>180.2[41.8]</td><td>190.5[6.4]</td><td>370.7[41.3]</td><td>196.8[29.3]</td><td>190.2[56.4]</td><td>387.0[39.8]<sup>a</sup></td></tr><tr><td colspan="7">Appointments</td></tr><tr><td>Total cost (US$) /day</td><td>8.65</td><td>6.49</td><td>7.53</td><td>8.01</td><td>6.12</td><td>7.08</td></tr><tr><td>Individual mean [SD] (US$)</td><td>0.17[0.08]</td><td>0.13[0.09]</td><td>0.15[0.07]</td><td>0.16[0.09]</td><td>0.12[0.08]</td><td>0.14[0.07]</td></tr><tr><td colspan="7">Laboratory tests</td></tr><tr><td>Total cost (US$) /day</td><td>38.07</td><td>25.35</td><td>31.48</td><td>33.33</td><td>22.96</td><td>28.24</td></tr><tr><td>Individual mean [SD] (US$)</td><td>0.75[0.74]</td><td>0.50[0.46]</td><td>0.62[0.43]</td><td>0.65[0.61]</td><td>0.45[0.43]</td><td>0.55[0.44]</td></tr><tr><td colspan="7">Procedures</td></tr><tr><td>Total cost (US$) /day</td><td>3.75</td><td>4.81</td><td>4.29</td><td>20.28</td><td>2.11</td><td>11.36</td></tr><tr><td>Individual mean [SD] (US$)</td><td>0.07[0.22]</td><td>0.09[0.21]</td><td>0.08[0.17]</td><td>0.40[1.11]</td><td>0.04[0.09]</td><td>0.22[0.57]</td></tr><tr><td colspan="7">Hospitalization</td></tr><tr><td>Total cost (US$) /day</td><td>2.62</td><td>2.53</td><td>2.57</td><td>2.30</td><td>1.17</td><td>1.74</td></tr><tr><td>Individual mean [SD] (US$)</td><td>0.05[0.30]</td><td>0.05[0.18]</td><td>0.05[0.17]</td><td>0.05[0.13]</td><td>0.02[0.10]</td><td>0.03[0.09]</td></tr><tr><td colspan="7">Pharmacist</td></tr><tr><td>Total cost (US$) /day</td><td>0.0</td><td>0.0</td><td>0.0</td><td>2.20</td><td>1.39</td><td>1.80</td></tr><tr><td>Individual mean [SD] (US$)</td><td>NA</td><td>NA</td><td>NA</td><td>0.05[0.02]</td><td>0.03[0.02]</td><td>0.04[0.02]</td></tr><tr><td colspan="7">Total</td></tr><tr><td>Final cost/day (US$)</td><td>53.09</td><td>39.18</td><td>45.88</td><td>66.13</td><td>33.74</td><td>50.23</td></tr><tr><td>Individual mean [SD] (US$)</td><td>1.04[0.99]</td><td>0.77[0.70]</td><td>0.90[0.60]</td><td>1.30[1.33]</td><td>0.66[0.55]</td><td>1.00[0.81]</td></tr><tr><td colspan="7">Total excluding procedures</td></tr><tr><td>Final cost/day (US$)</td><td>49.34</td><td>34.36</td><td>41.58</td><td>45.84</td><td>31.63</td><td>38.87</td></tr><tr><td>Individual mean [SD] (US$)</td><td>0.97[0.94]</td><td>0.67[0.63]</td><td>0.82[0.56]</td><td>0.90[0.71]</td><td>0.62[0.05]</td><td>0.77[0.53]</td></tr></table> |
4e7ef5c920c42affb2c0f2a20bcf0a4dbc5cbe2fe6fef2db6b06f29e8bfebb81.png | complex | <table><tr><td>Variables</td><td>Results</td></tr><tr><td colspan="2">Demographic variables:</td></tr><tr><td> Age, years</td><td>53.3 (8.7) (28–68)</td></tr><tr><td> Gender, F/M</td><td>34 (82.9)/ 7 (17)</td></tr><tr><td colspan="2">Cardiovascular risk factors:</td></tr><tr><td> Family history of CVD</td><td>20 (48.8)</td></tr><tr><td> Current/Ex-smokers</td><td>23 (56.1)</td></tr><tr><td> Hypertension</td><td>17 (41.5)</td></tr><tr><td> Diabetes</td><td>3 (7.3)</td></tr><tr><td> CKD3a (eGFR 45–59 ml/min/1.73 m<sup>2</sup>)</td><td>2 (4.9)</td></tr><tr><td> AI abnormal</td><td>11 (26.8)</td></tr><tr><td> BMI > 30 kg/m<sup>2</sup></td><td>5 (12.2)</td></tr><tr><td> Physical inactivity</td><td>23 (56.1)</td></tr><tr><td colspan="2">RA related variables</td></tr><tr><td> Disease duration, years</td><td>19.2 (9.2) (8–45)</td></tr><tr><td> Erosions (X-ray of hands/feet)</td><td>35 (85.4)</td></tr><tr><td> Extra-articular symptoms</td><td>28 (68.3)</td></tr><tr><td> Positive RF-IgM</td><td>33 (80.5)</td></tr><tr><td> Positive anti-CCP2</td><td>30 (73.2)</td></tr><tr><td> ESR, mm/h</td><td>19.2 (16.0) (2–64)</td></tr><tr><td> CRP, mg/l</td><td>14.35 (37.5) (0.1–228.5)</td></tr><tr><td> Average CRP (6 years), mg/l</td><td>11.02 (9.9) (0.9–37.3)</td></tr><tr><td> Low RA activity (DAS28 ≤ 3.2)</td><td>23 (56.1)</td></tr><tr><td> Current glucocorticoid use</td><td>18 (43.9)</td></tr><tr><td> Current conventional synthetic DMARD</td><td>39 (95.1)</td></tr><tr><td> Current biological DMARD</td><td>32 (78.1)</td></tr></table> |
9c0916ddaf995ec888622dd5921e0a3c81ba8e17fe830b2a33f534927076b6bb.png | complex | <table><tr><td></td><td colspan="3">Vaginal delivery</td><td colspan="3">Uterine rupture</td><td colspan="3">Maternal morbidity*</td><td colspan="3">Perinatal morbidity**</td></tr><tr><td>Type of labor</td><td>n (%)</td><td>OR (95% CI)</td><td>p</td><td>n (%)</td><td>OR (95% CI)</td><td>p</td><td>n (%)</td><td>OR (95% CI)</td><td>p</td><td>n (%)</td><td>OR (95% CI)</td><td>p</td></tr><tr><td>Spontaneous n=1,828 (51.6)</td><td>1,483 (81.1)</td><td>Ref</td><td></td><td>13 (0.7)</td><td>Ref</td><td></td><td>17 (0.9)</td><td>Ref</td><td></td><td>6 (0.3)</td><td>Ref</td><td></td></tr><tr><td>Induction or augmentation n=1,716 (48.4)</td><td>1,221 (71.2)</td><td>0.69 [0.49-0.67]</td><td><0.01</td><td>18 (1.0)</td><td>1.5 [0.7-3.0]</td><td>0.28</td><td>26 (1.5)</td><td>1.6 [0.9-3.0]</td><td>0.11</td><td>9 (0.5)</td><td>1.6 [0.6-4.5]</td><td>0.37</td></tr><tr><td>Prostaglandins n=515 (14.5)</td><td>323 (62.7)</td><td>0.39 [0.32-0.48]</td><td><0.01</td><td>4 (0.8)</td><td>1.1 [0.4-3.4]</td><td>0.88</td><td>6 (1.2)</td><td>1.3 [0.5-3.2]</td><td>0.63</td><td>4 (0.8)</td><td>2.4 [0.7-8.5]</td><td>0.18</td></tr><tr><td>Oxytocin (only) n=1,201 (33.9)</td><td>898 (74.8)</td><td>0.69 [0.58-0.82]</td><td><0.01</td><td>14 (1.2)</td><td>1.6 [0.8-3.5]</td><td>0.20</td><td>20 (1.7)</td><td>1.8 [0.9-3.5]</td><td>0.08</td><td>5 (0.4)</td><td>1.3 [0.4-4.2]</td><td>0.70</td></tr><tr><td>Prostaglandins (only) n=274 (7.7)</td><td>165 (60.2)</td><td>0.35 [0.27-0.46]</td><td><0.01</td><td>2 (0.7)</td><td>1.0 [0.2-4.5]</td><td>0.97</td><td>3 (1.1)</td><td>1.2 [0.3-4.0]</td><td>0.79</td><td>2 (0.7)</td><td>2.2 [0.4-11.1]</td><td>0.33</td></tr><tr><td>Prostaglandins + Oxytocin n=241 (6.8)</td><td>158 (65.6)</td><td>0.44 [0.33-0.59]</td><td><0.01</td><td>2 (0.8)</td><td>1.2 [0.3-5.2]</td><td>0.84</td><td>3 (1.2)</td><td>1.3 [0.4-4.6]</td><td>0.64</td><td>2 (0.8)</td><td>2.5 [0.5-12.7]</td><td>0.25</td></tr><tr><td>Oxytocin (induction) n=251 (7.1)</td><td>193 (76.9)</td><td>0.77 [0.56-1.06]</td><td>0.14</td><td>3 (1.2)</td><td>1.7 [0.5-6.0]</td><td>0.41</td><td>4 (1.6)</td><td>1.7 [0.6-5.2]</td><td>0.33</td><td>0 (0.0)</td><td>NA</td><td></td></tr><tr><td>Oxytocin (augmentation) n=950 (26.8)</td><td>705 (74.2)</td><td>0.67 [0.56-0.81]</td><td><0.01</td><td>11 (1.2)</td><td>1.6 [0.7-3.7]</td><td>0.23</td><td>16 (1.7)</td><td>1.8 [0.9-3.6]</td><td>0.09</td><td>5 (0.5)</td><td>1.6 [0.5-5.3]</td><td>0.44</td></tr><tr><td>Total N=3,544 (100)</td><td>2,704 (76.3)</td><td></td><td></td><td>31 (0.9)</td><td></td><td></td><td>43 (1.2)</td><td></td><td></td><td>15 (0.4)</td><td></td><td></td></tr></table> |
58e65be9e08e4cb99c7f3b3deb14c9d63e8226fc58490162c88bca058255aa64.png | simple | <table><tr><td>Source</td><td><i>F</i> statistic</td><td><i>p</i></td><td>Estimated means (standard error)</td></tr><tr><td>Talker variability</td><td>0.505</td><td>0.481</td><td>0 4.351 (0.101) single-talker</td></tr><tr><td></td><td></td><td></td><td>4.289 (0.089) multiple-talker</td></tr><tr><td>Talker Variability × Modality of Presentation</td><td>0.000</td><td>0.988</td><td>4.282 (0.143) audio only single-talker</td></tr><tr><td></td><td></td><td></td><td>4.221 (0.125) audio only multiple-talkers</td></tr><tr><td></td><td></td><td></td><td>4.420 (0.143) audio-visual single-talker</td></tr><tr><td></td><td></td><td></td><td>4.357 (0.125) audio-visual multiple-talkers</td></tr><tr><td>Modality of presentation</td><td>0.653</td><td>0.423</td><td>4.252 (0.120) audio-only</td></tr><tr><td></td><td></td><td></td><td>4.389 (0.120) audio-visual</td></tr></table> |
d99e7b15ddc37d306ca9cd52068d6913e9b47470d2f82a85077b908bc22c7767.png | complex | <table><tr><td>Characteristics</td><td>All patients (<i>n</i> = 468)</td><td>Phase I (<i>n</i> = 281)</td><td>Phase II (<i>n</i> = 187)</td><td><i>P</i> value</td></tr><tr><td>Age, years</td><td>60.4 ± 16.2</td><td>59.7 ± 17.7</td><td>61.4 ± 13.5</td><td>0.255</td></tr><tr><td>Female sex, <i>n</i> (%)</td><td>172 (36.8)</td><td>103 (36.7)</td><td>69 (36.9)</td><td>1.000</td></tr><tr><td>APACHE II score</td><td>26.1 ± 8.3</td><td>25.4 ± 8.2</td><td>27.2 ± 8.2</td><td>0.018*</td></tr><tr><td>Weight, kg</td><td>63.7 ± 17.8</td><td>63.7 ± 17.8</td><td>63.6 ± 18.0</td><td>0.946</td></tr><tr><td>Ventilated days preextubation, median (IQR)</td><td>2 (1–4)</td><td>2 (1–4)</td><td>3 (1–5)</td><td>0.509</td></tr><tr><td>Main diagnosis, <i>n</i> (%)</td><td></td><td></td><td></td><td>0.085</td></tr><tr><td> Pneumonia</td><td>130 (27.8)</td><td>67 (23.8)</td><td>63 (33.7)</td><td rowspan="8"></td></tr><tr><td> Nonpneumonia sepsis</td><td>72 (15.4)</td><td>45 (16.0)</td><td>27 (14.4)</td></tr><tr><td> COPD</td><td>16 (3.4)</td><td>7 (2.5)</td><td>9 (4.8)</td></tr><tr><td> Asthma</td><td>29 (6.2)</td><td>16 (5.7)</td><td>13 (7.0)</td></tr><tr><td> Fluid overload</td><td>32 (6.8)</td><td>21 (7.5)</td><td>11 (5.8)</td></tr><tr><td> Stroke</td><td>11 (2.4)</td><td>10 (3.6)</td><td>1 (0.5)</td></tr><tr><td> Seizure</td><td>30 (6.4)</td><td>19 (6.8)</td><td>11 (5.9)</td></tr><tr><td> Other<sup>a</sup></td><td>148 (31.6)</td><td>96 (34.2)</td><td>52 (27.8)</td></tr><tr><td colspan="5">Comorbidity, <i>n</i> (%)</td></tr><tr><td> Diabetes mellitus</td><td>184 (39.4)</td><td>100 (35.7)</td><td>84 (44.9)</td><td>0.053</td></tr><tr><td> Hypertension</td><td>255 (54.6)</td><td>151 (53.9)</td><td>104 (55.6)</td><td>0.776</td></tr><tr><td> IHD</td><td>111 (23.8)</td><td>60 (21.4)</td><td>51 (27.3)</td><td>0.151</td></tr><tr><td> CHF</td><td>38 (8.1)</td><td>14 (5.0)</td><td>24 (12.8)</td><td>0.003*</td></tr><tr><td> Asthma</td><td>66 (14.1)</td><td>37 (13.2)</td><td>29 (15.5)</td><td>0.500</td></tr><tr><td> COPD</td><td>30 (6.4)</td><td>14 (5.0)</td><td>16 (8.6)</td><td>0.129</td></tr><tr><td> Bronchiectasis</td><td>8 (1.7)</td><td>1 (0.4)</td><td>7 (3.7)</td><td>0.008*</td></tr><tr><td> OSA</td><td>23 (4.9)</td><td>12 (4.3)</td><td>11 (5.9)</td><td>0.514</td></tr><tr><td> CKD</td><td>107 (23.0)</td><td>59 (21.2)</td><td>48 (25.7)</td><td>0.263</td></tr><tr><td> CLD</td><td>26 (5.6)</td><td>18 (6.4)</td><td>8 (4.3)</td><td>0.411</td></tr><tr><td> Stroke</td><td>59 (12.7)</td><td>40 (14.3)</td><td>19 (10.2)</td><td>0.204</td></tr><tr><td> Cancer</td><td>34 (12.1)</td><td>24 (12.8)</td><td>24 (12.8)</td><td>0.886</td></tr></table> |
6313b6bd18c6449606d60d515686e1170de18d3d3f65cba9c3eb8461492b413d.png | complex | <table><tr><td></td><td>Before</td><td>After</td><td><i>P</i> value</td><td>ES</td><td>IC</td></tr><tr><td colspan="6">External rotator</td></tr><tr><td> Positive peak torque at 60 deg.s<sup>−1</sup> (Nm)</td><td>43.3 ± 7.7*</td><td>40.6 ± 6.4</td><td>0.02</td><td>0.38</td><td>−0.13 to −0.63</td></tr><tr><td> Positive total work at 60 deg.s<sup>−1</sup> (J)</td><td>51.7 ± 9.8*</td><td>46.7 ± 8.5</td><td>0.01</td><td>0.54</td><td>−0.24 to-0.84</td></tr><tr><td> Positive peak torque at 300 deg.s<sup>−1</sup> (Nm)</td><td>35.2 ± 5.0</td><td>34.5 ± 2.5</td><td>0.41</td><td>0.17</td><td>0.19 to −0.53</td></tr><tr><td> Average power at 300 deg.s<sup>−1</sup> (W)</td><td>65.3 ± 14.4</td><td>59.2 ± 10.3</td><td>0.12</td><td>0.48</td><td>0.032 to −0.99</td></tr><tr><td> Negative peak torque at 90 deg.s<sup>−1</sup> (Nm)</td><td>45.2 ± 9.8</td><td>38.9 ± 9.5</td><td>0.06</td><td>0.65</td><td>−0.096 to −1.2</td></tr><tr><td> Negative peak torque at 300 deg.s<sup>−1</sup> (Nm)</td><td>44.7 ± 6.2*</td><td>40.4 ± 4.5</td><td>0.04</td><td>0.79</td><td></td></tr><tr><td colspan="6">Internal rotator</td></tr><tr><td> Positive peak torque at 60 deg.s<sup>−1</sup> (Nm)</td><td>71.3 ± 13.7*</td><td>60.9 ± 10.2</td><td>0.01</td><td>0.86</td><td>−0.37 to −1.3</td></tr><tr><td> Positive total work at 60 deg.s<sup>−1</sup> (J)</td><td>90.9 ± 16.9*</td><td>77.8 ± 13.1</td><td>0.00</td><td>0.86</td><td>−0.86 to −0.86</td></tr><tr><td> Positive peak torque at 300 deg.s<sup>−1</sup> (Nm)</td><td>66.5 ± 12.3*</td><td>61.3 ± 12.3</td><td>0.00</td><td>0.42</td><td>−0.42 to −0.42</td></tr><tr><td> Average power at 300 deg.s<sup>−1</sup> (W)</td><td>113.3 ± 29.4*</td><td>94.8 ± 29.1</td><td>0.02</td><td>0.63</td><td>−0.22 to −1</td></tr><tr><td> Negative peak torque at 90 deg.s<sup>−1</sup> (Nm)</td><td>79.8 ± 13.6</td><td>68.9 ± 17.2</td><td>0.06</td><td>0.70</td><td>−0.1 to −1.3</td></tr><tr><td> Negative peak torque at 300 deg.s<sup>−1</sup> (Nm)</td><td>69.9 ± 14.6</td><td>62.9 ± 12.9</td><td>0.16</td><td>0.51</td><td>0.051 to −1.1</td></tr><tr><td colspan="6">Balance ratios</td></tr><tr><td> Conventional ratio</td><td>0.61 ± 0.1</td><td>0.67 ± 0.1</td><td>0.063</td><td>0.60</td><td>−0.081 to −1.1</td></tr><tr><td> Functional ratio</td><td>0.68 ± 0.1</td><td>0.67 ± 0.2</td><td>0.806</td><td>0.06</td><td>0.37 to −0.49</td></tr></table> |
e9087d2645cc1ac294afa7e2a72c18c54f7c4496b8a6731d518c756f5906165d.png | simple | <table><tr><td>AC</td><td>Date of creation</td><td>Ground-truth location(s)</td><td>Prediction results</td><td>GO total number</td><td>Essential GO terms</td></tr><tr><td>D3DTV9</td><td>26-Nov-2014</td><td>Nucleus</td><td>Nucleus</td><td>13</td><td>GO:0000166, GO:0016787, GO:0003676, GO:0003723, GO:0004386, GO:0046872, GO:0051607, GO:0005524</td></tr><tr><td>E9PAV3</td><td>19-Feb-2014</td><td>Cytoplasm, Nucleus</td><td>Cytoplasm, Nucleus</td><td>9</td><td>GO:0015031, GO:0003677, GO:0005634, GO:0005737, GO:0006351, GO:0006355, GO:0006810</td></tr><tr><td>B7ZW38</td><td>26-Nov-2014</td><td>Nucleus</td><td>Nucleus</td><td>5</td><td>GO:0000166, GO:0030529, GO:0003676, GO:0003723, GO:0005634</td></tr><tr><td>P0DMR3</td><td>07-Jan-2015</td><td>Cytoplasm</td><td>Cytoplasm</td><td>22</td><td>GO:0000166, GO:0016740, GO:0016874, GO:0003824, GO:0046872, GO:0005524, GO:0005575, GO:0008152</td></tr><tr><td>P0DML3</td><td>09-Jul-2014</td><td>Extracellular</td><td>Extracellular</td><td>6</td><td>GO:0046872, GO:0005179, GO:0005576, GO:0007165</td></tr><tr><td>P0DMN0</td><td>03-Sep-2014</td><td>Cytoplasm</td><td>Cytoplasm</td><td>16</td><td>GO:0016740, GO:0030968, GO:0044267, GO:0044281, GO:0005737, GO:0005829, GO:0006629, GO:0006805</td></tr><tr><td>C9JSJ3</td><td>29-Oct-2014</td><td>Nucleus</td><td>Nucleus</td><td>4</td><td>GO:0003677, GO:0005634, GO:0006351, GO:0006355</td></tr></table> |
b7a41ba1aab4c27bdb58a405f6133aaabda6abf59acf3f291dfc8e5ce838fe1d.png | simple | <table><tr><td>Parameter</td><td><i> R </i></td><td><i>P</i> value</td></tr><tr><td>W/H</td><td>0.55</td><td><0.0001</td></tr><tr><td>BMI</td><td>0.264</td><td>0.017</td></tr><tr><td>TG</td><td>0.23</td><td>0.037</td></tr><tr><td>Chol</td><td>−0.04</td><td>0.86</td></tr><tr><td>LDL-C</td><td>−0.038</td><td>0.73</td></tr><tr><td>HDL-C</td><td>−0.21</td><td>0.05</td></tr><tr><td>VLDL-C</td><td>0.23</td><td>0.03</td></tr><tr><td>ApoB</td><td>0.087</td><td>0.44</td></tr><tr><td>ApoA1</td><td>−0.204</td><td>0.06</td></tr><tr><td>TG/HDL-C</td><td>0.283</td><td>0.01</td></tr><tr><td>LDL-C/HDL-C</td><td>0.13</td><td>0.24</td></tr><tr><td>LDL size</td><td>−0.25</td><td>0.025</td></tr></table> |
003ef5c833e23bb8c08a06db267c2e04cfbfd89a7f23de8d0165b69b81985730.png | complex | <table><tr><td rowspan="2">DEC2</td><td colspan="4">HIF-1α expression scale*</td><td rowspan="2">Total</td></tr><tr><td>0</td><td>1</td><td>2</td><td>3</td></tr><tr><td>0</td><td>0 (0%)</td><td>4 (8%)</td><td>2 (4%)</td><td>1 (2%)</td><td>7 (14%)</td></tr><tr><td>1</td><td>2 (4%)</td><td>13 (26%)</td><td>11 (22%)</td><td>4 (8%)</td><td>30 (60%)</td></tr><tr><td>2</td><td>0 (0%)</td><td>2 (4%)</td><td>2 (4%)</td><td>7 (14%)</td><td>11 (22%)</td></tr><tr><td>3</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>2 (4%)</td><td>2 (4%)</td></tr><tr><td>Total</td><td>2 (4%)</td><td>19 (38%)</td><td>15 (30%)</td><td>14 (28%)</td><td>50 (100%)</td></tr></table> |
eff393e3bd3d85b392c1d7e84ba8ec8d67e81c003e20913531e30fb8f1bc75b9.png | complex | <table><tr><td> </td><td colspan="2">FNA</td><td colspan="2">CB</td><td colspan="2">FNA and CB</td></tr><tr><td>Suspected hepatic metastasis</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Specific diagnosis</td><td>56%</td><td>(70/124)</td><td>68%</td><td>(34/50)</td><td>60% </td><td>(75/124)</td></tr><tr><td><sup> ∗</sup>Diagnosis malignant versus benign</td><td>93% </td><td>(115/124)</td><td>96% </td><td>(48/50)</td><td>94%</td><td>(117/124)</td></tr><tr><td>Suspected primary neoplasms</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Specific diagnosis</td><td>70.5%</td><td>(43/61)</td><td>67.5%</td><td>(27/40)</td><td>79%</td><td>(48/61)</td></tr><tr><td>Total</td><td>85.4%</td><td>(158/185)</td><td>83%</td><td>(75/90)</td><td>89.1%</td><td>(165/185)</td></tr></table> |
61b7ffc5dab716c7d744668bb541e0fe8987faa6e651443bb5f5af82a315a89a.png | complex | <table><tr><td colspan="4">Patients (n = 458)</td></tr><tr><td>Baseline characteristics</td><td> </td><td>% or mean</td><td>(n or SD)</td></tr><tr><td>Men%</td><td> </td><td>24.9</td><td>(114)</td></tr><tr><td>Women%</td><td> </td><td>74.7</td><td>(342)</td></tr><tr><td>Age mean years (SD)</td><td> </td><td>54.0</td><td>(7.4)</td></tr><tr><td>Weight mean kg (SD)</td><td> </td><td>96.4</td><td>(18.3)</td></tr><tr><td>Starting BMI mean kg/m<sup>2</sup> (SD)</td><td> </td><td>36.0</td><td>(5.9)</td></tr><tr><td>Starting BMI kg/m<sup>2</sup>%</td><td><30</td><td>9.8</td><td>(45)</td></tr><tr><td> </td><td>30-34</td><td>43.9</td><td>(201)</td></tr><tr><td> </td><td>35-39</td><td>23.8</td><td>(109)</td></tr><tr><td> </td><td>≥40</td><td>21.2</td><td>(97)</td></tr><tr><td> </td><td>not recorded</td><td>1.3</td><td>(6)</td></tr><tr><td>Smoking status%</td><td>smoker</td><td>14.4</td><td>(66)</td></tr><tr><td> </td><td>not recorded</td><td>18.8</td><td>(86)</td></tr><tr><td>Diabetes Status%</td><td>diabetic</td><td>11.6</td><td>(53)</td></tr><tr><td> </td><td>not recorded</td><td>15.7</td><td>(72)</td></tr></table> |
f6be55fc148a051162e7e789ef16df8a19da52395429774a101ab536436c575f.png | complex | <table><tr><td> </td><td> </td><td colspan="8">Photographic ICDAS score UR6 occlusal</td></tr><tr><td> </td><td> </td><td>0</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>F</td><td>S</td></tr><tr><td>Clinical ICDAS Score UR6 Occlusal</td><td>0</td><td>506</td><td>8</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2</td><td>5</td></tr><tr><td> </td><td>2</td><td>252</td><td>327</td><td>26</td><td>4</td><td>2</td><td>0</td><td>7</td><td>7</td></tr><tr><td> </td><td>3</td><td>2</td><td>66</td><td>48</td><td>3</td><td>1</td><td>0</td><td>1</td><td>1</td></tr><tr><td> </td><td>4</td><td>2</td><td>25</td><td>15</td><td>25</td><td>4</td><td>0</td><td>1</td><td>1</td></tr><tr><td> </td><td>5</td><td>0</td><td>1</td><td>5</td><td>1</td><td>7</td><td>0</td><td>2</td><td>1</td></tr><tr><td> </td><td>6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>7</td><td>0</td><td>0</td></tr><tr><td> </td><td>F</td><td>10</td><td>3</td><td>0</td><td>0</td><td>0</td><td>0</td><td>138</td><td>4</td></tr><tr><td> </td><td>S</td><td>4</td><td>1</td><td>2</td><td>0</td><td>0</td><td>0</td><td>12</td><td>187</td></tr></table> |
d6f23eb6c00bcab77f4729771404514862c8794bbe9ae022d25120c581866710.png | simple | <table><tr><td>Variables</td><td>Comparative group</td><td>Intervention group</td></tr><tr><td>Sex </td><td> </td><td> </td></tr><tr><td> Male </td><td>382 (62.2%)</td><td>511 (73.3%)</td></tr><tr><td> Female </td><td>232 (37.78%)</td><td>186 (26.7%)</td></tr><tr><td>Age </td><td> </td><td> </td></tr><tr><td> 18–24</td><td>608 (99%)</td><td>657 (94.3%)</td></tr><tr><td> 25–30</td><td>6 (1%)</td><td>40 (5.7%)</td></tr><tr><td>Religion </td><td> </td><td> </td></tr><tr><td> Orthodox </td><td>321 (52.3%)</td><td>341 (48.9%)</td></tr><tr><td> Catholic </td><td>32 (5.2%)</td><td>17 (2.4%)</td></tr><tr><td> Protestant </td><td>153 (24.9%)</td><td>150 (21.5%)</td></tr><tr><td> Muslim </td><td>100 (16.3%)</td><td>165 (23.7%)</td></tr><tr><td> Other<sup><i>∗</i></sup></td><td>8 (1.3%)</td><td>24 (3.4%)</td></tr><tr><td>Ethnic group </td><td> </td><td> </td></tr><tr><td> Oromo </td><td>362 (59%)</td><td>495 (71%)</td></tr><tr><td> Amhara </td><td>150 (24.4%)</td><td>106 (15.2%)</td></tr><tr><td> Tigrea</td><td>32 (5.2%)</td><td>30 (4.3%)</td></tr><tr><td> Sidama </td><td>22 (3.6%)</td><td>21 (3%)</td></tr><tr><td> Gurage</td><td>6 (1%)</td><td>24 (3.4%)</td></tr><tr><td> Other<sup><i>∗∗</i></sup></td><td>42 (6.8%)</td><td>21 (3%)</td></tr><tr><td>Marital status </td><td> </td><td> </td></tr><tr><td> Single </td><td>567 (92.3%)</td><td>586 (84.1%)</td></tr><tr><td> In relationship </td><td>41 (6.7%)</td><td>85 (12.2%)</td></tr><tr><td> Married </td><td>6 (1%)</td><td>26 (3.7%)</td></tr><tr><td>Income </td><td> </td><td> </td></tr><tr><td> <300</td><td>418 (68%)</td><td>514 (73.7%)</td></tr><tr><td> >300</td><td>196 (32%)</td><td>183 (26.3%)</td></tr></table> |
ed87e0e53d718a4e4ecef294da682b8f1d02525d823d59dbc5fd3ab4dbdbcc3f.png | simple | <table><tr><td>Immersion Time/h</td><td>EV-0.1 MPa</td><td>EV-3.5 MPa</td><td>EGF-0.1 MPa</td><td>EGF-3.5 MPa</td></tr><tr><td>12</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td></tr><tr><td>24</td><td>6.02</td><td>−4.01</td><td>6.42</td><td>2.31</td></tr><tr><td>36</td><td>−2.02</td><td>3.07</td><td>−1.79</td><td>0.27</td></tr><tr><td>48</td><td>−4.49</td><td>0.52</td><td>0.77</td><td>−3.53</td></tr><tr><td>60</td><td>−1.18</td><td>1.67</td><td>−4.56</td><td>−0.31</td></tr><tr><td>72</td><td>−2.81</td><td>−2.49</td><td>−5.81</td><td>−0.84</td></tr><tr><td>84</td><td>0.68</td><td>2.24</td><td>−6.53</td><td>2.89</td></tr><tr><td>96</td><td>−7.43</td><td>4.70</td><td>−4.47</td><td>−3.48</td></tr><tr><td>108</td><td>−1.36</td><td>−5.6</td><td>0.35</td><td>1.04</td></tr><tr><td>120</td><td>1.43</td><td>5.04</td><td>3.28</td><td>−1.55</td></tr><tr><td>132</td><td>7.56</td><td>−3.64</td><td>10.83</td><td>0.00</td></tr><tr><td>144</td><td>6.07</td><td>−4.95</td><td>11.19</td><td>7.63</td></tr><tr><td>156</td><td>8.45</td><td>1.01</td><td>4.10</td><td>−4.63</td></tr><tr><td>168</td><td>4.58</td><td>−2.82</td><td>12.40</td><td>3.79</td></tr><tr><td>180</td><td>7.23</td><td>5.56</td><td>−2.48</td><td>−6.25</td></tr><tr><td>192</td><td>0.93</td><td>−11.27</td><td>9.56</td><td>3.34</td></tr></table> |
4a3f013c054b3fc6683f0217dec251d03b9a03b35edee1d876b5ed69ed03d8fe.png | simple | <table><tr><td> </td><td>Mean value of MI</td><td>Standard deviation of MI</td><td>Num of positive values</td><td>Num of negative values</td><td>Num of values ofdifferent sign</td><td>Min value</td><td>Max value</td></tr><tr><td>GSE18655_grade1</td><td>0.00024</td><td>0.0015</td><td>6298</td><td>2918</td><td>N/A</td><td>−0.0011</td><td>0.0858</td></tr><tr><td>GSE18655_grade2</td><td>0.00020</td><td>0.0017</td><td>6468</td><td>2748</td><td> </td><td>−0.0018</td><td>0.0949</td></tr><tr><td>GSE18655_grade3</td><td>0.0004</td><td>0.0021</td><td>6650</td><td>2566</td><td> </td><td>−0.0029</td><td>0.0582</td></tr><tr><td>GSE19536_A(72)</td><td>0.00036</td><td>0.0022</td><td>3912</td><td>1272</td><td>2052</td><td>−0.0010</td><td>0.1293</td></tr><tr><td>GSE19536_B(72)</td><td>0.00053</td><td>0.0040</td><td>3388</td><td>1796</td><td> </td><td>−0.0022</td><td>0.2279</td></tr><tr><td>GSE19536_BasalLike(68)</td><td>0.0017</td><td>0.0056</td><td>3491</td><td>998</td><td>1217</td><td>−0.0033</td><td>0.1648</td></tr><tr><td>GSE19536_NormalLike(68)</td><td>0.0056</td><td>0.008</td><td>4200</td><td>420</td><td> </td><td>−0.002</td><td>0.1279</td></tr><tr><td>GSE21036_cancer</td><td>0.0165</td><td>0.0212</td><td>10</td><td>474</td><td>56</td><td>−0.002</td><td>0.1446</td></tr><tr><td>GSE21036_norm</td><td>0.0086</td><td>0.0146</td><td>46</td><td>438</td><td> </td><td>−0.0015</td><td>0.1565</td></tr></table> |
2169910044876a10710d5cfe4e36a7ff6f32feaea2ba346bf7dc1f30b760af86.png | simple | <table><tr><td>Complication</td><td>EN group(n = 8)</td><td>EN+PN group(n = 9)</td></tr><tr><td>Surgery related complications</td><td></td><td></td></tr><tr><td> Pancreatic leakage (minor leakage)</td><td>0</td><td>1</td></tr><tr><td> Anastomotic leakage (minor leakage)</td><td>1</td><td>0</td></tr><tr><td> Ileus</td><td>1</td><td>0</td></tr><tr><td> Ulcer at anastomotic portion</td><td>0</td><td>1</td></tr><tr><td> Wound infection</td><td>3</td><td>1</td></tr><tr><td>General complications</td><td></td><td></td></tr><tr><td> Pulmonary</td><td>1</td><td>0</td></tr><tr><td>Total number of patients with complications</td><td>5</td><td>4</td></tr><tr><td>Mortality</td><td>1</td><td>0</td></tr><tr><td>No significant differences noted.</td><td></td><td></td></tr></table> |
f0b07ac05b82372c5a5d3512e77ba7f8d3eb8e4b98aa2c758e47905ca6f1fb13.png | complex | <table><tr><td rowspan="2">Food outlets</td><td rowspan="2">Accessibility/availability measures</td><td colspan="2">All cases</td><td colspan="2">Type 1 diabetes</td><td colspan="2">Type 2 diabetes</td></tr><tr><td>Mean (SD)</td><td>Range</td><td>Mean (SD)</td><td>Range</td><td>Mean (SD)</td><td>Range</td></tr><tr><td rowspan="3">Supermarket</td><td>Distance to nearest (miles)</td><td>2.9 (2.7)</td><td>0.0, 17.4</td><td>2.9 (2.6)</td><td>0.0, 15.6</td><td>3.1 (3.1)</td><td>0.2, 17.4</td></tr><tr><td>Number in 2-mile buffer</td><td>1.1 (1.5)</td><td>0.0, 9.0</td><td>1.1 (1.6)</td><td>0.0, 9.0</td><td>1.2 (1.4)</td><td>0.0, 6.0</td></tr><tr><td>Density (number per sq. mile)</td><td>1.1 (0.7)</td><td>0.0, 2.6</td><td>1.1 (0.7)</td><td>0.0, 2.5</td><td>1.1 (0.8)</td><td>0.0, 2.6</td></tr><tr><td rowspan="3">Fast food</td><td>Distance to nearest (miles)</td><td>2.6 (2.5)</td><td>0.0, 15.9</td><td>2.5 (2.4)</td><td>0.0, 15.9</td><td>2.9 (3.1)</td><td>0.2, 15.7</td></tr><tr><td>Number in 1-mile buffer</td><td>1.2 (2.7)</td><td>0.0, 17.0</td><td>1.2 (2.7)</td><td>0.0, 17.0</td><td>1.4 (2.7)</td><td>0.0, 14.0</td></tr><tr><td>Density (number per sq. mile)</td><td>1.7 (2.0)</td><td>0.0, 9.8</td><td>1.7 (2.0)</td><td>0.0, 9.2</td><td>1.8 (2.1)</td><td>0.0, 9.8</td></tr></table> |
87cd60a52226c36a42f343a686c43402dc399ffa5c316bbb9d3c43b4b9b6fdc6.png | simple | <table><tr><td>Category</td><td>Age (years)</td><td>Hb (g/dL)</td><td>Parasite density (% of parasitized RBCs)</td></tr><tr><td>Complicated cases</td><td>2.384 (±1.239)</td><td>9.579 (±0.900)</td><td>10.542 (±2.704)</td></tr><tr><td>Uncomplicated controls</td><td>2.796 (±1.315)</td><td>12.338 (±1.278)</td><td>7.596 (±2.040)</td></tr><tr><td><i>P</i> value</td><td><i>0.007</i></td><td><i><0.0001</i></td><td><i><0.0001</i></td></tr></table> |
6ff95671106fa24dd133cd1dac1e0ffeebb4b6dff57707e1c0e7e12e874dacff.png | simple | <table><tr><td>Patients/reference group</td><td>Mean</td><td>SD</td><td>Comment Original publication</td></tr><tr><td>MS</td><td>35.4</td><td>12.1</td><td>Present data</td></tr><tr><td>Stroke</td><td>42.1</td><td>12.7</td><td>Present data</td></tr><tr><td>Male, age 40–49</td><td>64.2</td><td>16.3</td><td>German Health Survey 1998 (20) (<i>N</i> = 6964 participants, age 18–80)</td></tr><tr><td>Male, age 50–59</td><td>61.5</td><td>18.1</td><td>German Health Survey 1998 (20)</td></tr><tr><td>Female, age 40–49</td><td>57.4</td><td>18.8</td><td>German Health Survey 1998 (20)</td></tr><tr><td>Female, age 50–59</td><td>57.7</td><td>18.8</td><td>German Health Survey 1998 (20)</td></tr></table> |
0a4e538a74bebafaf314a161f5ee04d90e9813a37058503d4dadcfe44145b057.png | simple | <table><tr><td>Parameter</td><td>Leaf oil </td><td>Bark oil </td></tr><tr><td>Specific gravity (20°C) </td><td>1.030–1.050 </td><td>1.010–1.030 </td></tr><tr><td>Optical rotation (°) (20°C) </td><td>1°96′–0°40′</td><td>Slightly laevorotatory </td></tr><tr><td>Refractive index (20°C) </td><td>1.529–1.537 </td><td>1.573–1.591 </td></tr><tr><td>Aldehyde content </td><td>4% </td><td>65–76% </td></tr><tr><td>Eugenol content </td><td>77.3–90.5% </td><td>4–10% </td></tr><tr><td>Solubility characteristics </td><td>Soluble in 1.5 volumes of 70% alcohol </td><td>Soluble in 2.0–3.0 volumes of 70% alcohol</td></tr></table> |
0e3db38e3b8a39c127a656208185d8652691954d02deb4b75db71bbec9b229ae.png | complex | <table><tr><td>Degree of comfort</td><td colspan="2">Attending to patients with mental illness</td><td colspan="2">Dealing with mentally sick people</td></tr><tr><td></td><td>Frequency</td><td>Percent</td><td>Frequency</td><td>Percent</td></tr><tr><td>Extremely uncomfortable</td><td>22</td><td>19.8</td><td>28</td><td>25.2</td></tr><tr><td>Uncomfortable</td><td>54</td><td>48.6</td><td>41</td><td>36.9</td></tr><tr><td>Comfortable</td><td>31</td><td>27.9</td><td>37</td><td>33.3</td></tr><tr><td>Extremely comfortable</td><td>4</td><td>3.6</td><td>5</td><td>4.5</td></tr><tr><td>TOTAL</td><td>111</td><td>100.0</td><td>111</td><td>100.0</td></tr></table> |
5f6ae1dc526bf783626982f4061ded6e0f047c92ebe5298bac2edb954e5ef693.png | complex | <table><tr><td rowspan="3">Weight (kg)</td><td colspan="2">Wafers or Bars per Day</td></tr><tr><td>BP-100<sup>TM</sup></td><td>NumTrey</td></tr><tr><td>Bar</td><td>Wafer</td></tr><tr><td>3.0–3.4</td><td>2</td><td>17</td></tr><tr><td>3.5–4.9</td><td>2.5</td><td>20</td></tr><tr><td>5.0–6.9</td><td>4</td><td>27</td></tr><tr><td>7.0–9.9</td><td>5</td><td>40</td></tr><tr><td>10.0–14.0</td><td>6</td><td>53</td></tr><tr><td>14.0–19.0</td><td>9.5</td><td>79</td></tr><tr><td>19.0–23.0</td><td>13</td><td>106</td></tr><tr><td>23.0–30.0</td><td>16</td><td>131</td></tr><tr><td>>30.0</td><td>200 kcal/kg/day</td><td>200 kcal/kg/day</td></tr></table> |
866d84fbb0f3e7f77d272b09b24832d5784cc6523c49e7975f74bebff7e40b41.png | complex | <table><tr><td>Variable</td><td colspan="2">PFS</td><td></td><td colspan="2">OS</td></tr><tr><td></td><td>Hazard ratio (95% CI)</td><td><i>P</i> value</td><td></td><td>Hazard ratio (95% CI)</td><td><i>P</i> value</td></tr><tr><td>Beclin 1 (high vs. low)</td><td>1.833 (1.016-3.308)</td><td>0.044</td><td></td><td>1.233 (0.861-1.766)</td><td>0.252</td></tr><tr><td>Age (≥56 y vs. <56 y)</td><td>0.695 (0.426-1.133)</td><td>0.144</td><td></td><td>1.166 (0.844-1.613)</td><td>0.352</td></tr><tr><td>Gender (Male vs. Female)</td><td>1.459 (0.864-2.464)</td><td>0.157</td><td></td><td>0.984 (0.703-1.379)</td><td>0.927</td></tr><tr><td>Subtypes (Intrahepatic vs. Extrahepatic)</td><td>0.596 (0.362-0.984)</td><td>0.043</td><td></td><td>0.614 (0.439-0.859)</td><td>0.004</td></tr><tr><td>Largest tumor size (≥5 cm vs. <5 cm)</td><td>1.934 (1.187-3.150)</td><td>0.008</td><td></td><td>1.903 (1.371-2.642)</td><td>< 0.001</td></tr><tr><td>Vascular invasion (Positive vs. Negative)</td><td>1.899 (1.168-3.086)</td><td>0.010</td><td></td><td>1.416 (1.014-1.977)</td><td>0.041</td></tr><tr><td>HBV infection (Positive vs. Negative)</td><td>1.620 (0.957-2.743)</td><td>0.072</td><td></td><td>1.139 (0.781-1.662)</td><td>0.498</td></tr><tr><td>Liver cirrhosis (Positive vs. Negative)</td><td>0.574 (0.312-1.056)</td><td>0.074</td><td></td><td>0.811 (0.518-1.267)</td><td>0.357</td></tr><tr><td>Cholecystolithiasis (Positive vs. Negative)</td><td>0.904 (0.474-1.727)</td><td>0.761</td><td></td><td>0.944 (0.614-1.452)</td><td>0.793</td></tr><tr><td>Histological grade (well/moderate vs. poor)</td><td>2.869 (1.508-5.458)</td><td>0.001</td><td></td><td>2.633 (1.714-4.043)</td><td>< 0.001</td></tr><tr><td>Tumor surgery (R0 vs. R1/R2)</td><td>3.465 (1.691-7.101)</td><td>0.001</td><td></td><td>3.095 (1.824-5.249)</td><td>< 0.001</td></tr><tr><td>Serum CA199 (≥35 unit/ml vs. <35 unit/ml)</td><td>1.857 (0.867-3.979)</td><td>0.111</td><td></td><td>1.477 (0.931-2.342)</td><td>0.097</td></tr><tr><td>Serum CA125 (≥35 unit/ml vs. <35 unit/ml)</td><td>1.844 (0.954-3.565)</td><td>0.069</td><td></td><td>1.679 (1.046-2.695)</td><td>0.032</td></tr><tr><td>Serum CEA (≥5 ug/L vs. <5 ug/L)</td><td>1.661 (0.911-3.029)</td><td>0.098</td><td></td><td>2.063 (1.394-3.053)</td><td>< 0.001</td></tr><tr><td>Serum AFP (≥8.1 ug/L vs. <8.1 ug/L)</td><td>1.096 (0.571-2.105)</td><td>0.783</td><td></td><td>1.019 (0.645-1.610)</td><td>0.936</td></tr><tr><td>Serum total bilirubin (≥23.9 umol/L vs. <23.9 umol/L)</td><td>0.762 (0.469-1.237)</td><td>0.272</td><td></td><td>0.801 (0.577-1.113)</td><td>0.187</td></tr><tr><td>Tumor stage (T1+2 vs. T3+4)</td><td>1.292 (0.781-2.139)</td><td>0.318</td><td></td><td>1.595 (1.131-2.249)</td><td>0.008</td></tr><tr><td>Node stage (N0 vs. N1)</td><td>1.330 (0.804-2.199)</td><td>0.266</td><td></td><td>1.416 (1.010-1.984)</td><td>0.043</td></tr><tr><td>TNM stage (1+2 vs. 3+4)</td><td>2.197 (1.332-3.623)</td><td>0.002</td><td></td><td>2.152 (1.541-3.006)</td><td>< 0.001</td></tr></table> |
72ee5c47052eee943ef41d7e00eb7856ec955f9a5a7e502fc495eea92c54f88a.png | simple | <table><tr><td>Nutritional regime</td><td>Males (N) Means ± SE (in days)</td><td>Females (N) Means ± SE (in days)</td><td>χ<sup>2</sup>*</td><td>P</td></tr><tr><td>Glucose (6%)</td><td>(148) 17.3 ± 0.6</td><td>(151) 17.2 ± 0.6</td><td>0.004</td><td>0.94</td></tr><tr><td><i>T. stans</i></td><td>(145) 14.2 ± 0.8</td><td>(154) 13.2 ± 0.6</td><td>0.89</td><td>0.34</td></tr><tr><td><i>S. didymobotrya</i></td><td>(131) 11.9 ± 0.5</td><td>(142) 11.4 ± 0.5</td><td>0.01</td><td>0.88</td></tr><tr><td><i>R. communis</i></td><td>(143) 10.9 ± 0.5</td><td>(142) 12.6 ± 0.6</td><td>3.07</td><td>0.07</td></tr><tr><td><i>H. patens</i></td><td>(136) 8.1 ± 0.4</td><td>(150) 7.4 ± 0.4</td><td>0.88</td><td>0.34</td></tr><tr><td><i>L. camara</i></td><td>(149) 7.6 ± 0.3</td><td>(145) 6.7 ± 0.3</td><td>2.93</td><td>0.08</td></tr><tr><td><i>P. hysterophorus</i></td><td>(138) 4.7 ± 0.3</td><td>(141) 4.7 ± 0.3</td><td>0.002</td><td>0.96</td></tr><tr><td>Water (-ve control)</td><td>(148) 3.8 ± 0.1</td><td>(149) 3.8 ± 0.1</td><td>0.01</td><td>0.90</td></tr><tr><td>None (2<sup>nd </sup>-ve control)</td><td>(144) 2.9 ± 0.07</td><td>(143) 3.1 ± 0.07</td><td>2.58</td><td>0.10</td></tr></table> |
602c333f3798c52718a26157de2212878e24c840aaec5c2feae2c7150a68c7bf.png | complex | <table><tr><td></td><td colspan="2">ATIC mRNA expression<sup>△</sup></td><td><i>p</i> value</td></tr><tr><td>Variable</td><td>Low (117)</td><td>high (117)</td><td>(chi-square)</td></tr><tr><td colspan="4">Gender</td></tr><tr><td> Male</td><td>83</td><td>81</td><td>0.8865</td></tr><tr><td> Female</td><td>34</td><td>36</td><td></td></tr><tr><td colspan="4">Diagnosis Age</td></tr><tr><td>≤ 50</td><td>23</td><td>30</td><td>0.3488</td></tr><tr><td>> 50</td><td>94</td><td>87</td><td></td></tr><tr><td colspan="4">AFP (ng/mL)</td></tr><tr><td>≤ 200</td><td>97</td><td>74</td><td>0.0011*</td></tr><tr><td>> 200</td><td>20</td><td>43</td><td></td></tr><tr><td colspan="4">Hepatitis status</td></tr><tr><td> Negative</td><td>61</td><td>44</td><td>0.0352*</td></tr><tr><td> Positive</td><td>56</td><td>73</td><td></td></tr><tr><td colspan="4">Vascular Invasion</td></tr><tr><td> No</td><td>85</td><td>69</td><td>0.0384*</td></tr><tr><td> Yes</td><td>32</td><td>48</td><td></td></tr><tr><td colspan="4">Histologic Grade</td></tr><tr><td> G1</td><td>17</td><td>9</td><td>0.0006*</td></tr><tr><td> G2</td><td>64</td><td>43</td><td></td></tr><tr><td> G3-G4</td><td>36</td><td>65</td><td></td></tr><tr><td colspan="4">TNM stage</td></tr><tr><td> I</td><td>78</td><td>56</td><td>0.0086*</td></tr><tr><td> II</td><td>24</td><td>31</td><td></td></tr><tr><td> III-IV</td><td>15</td><td>30</td><td></td></tr></table> |
48b5c77d7db59a5586a0f99ba85980656165f835702f5429eb0f5d01073b7dc9.png | complex | <table><tr><td>Subset</td><td>Reference range</td><td colspan="3">Probands</td><td>Goodness of fit</td><td colspan="3">Spouses</td><td>Goodness of fit</td></tr><tr><td></td><td>% subset sum</td><td>% below</td><td>% within</td><td>% above</td><td>p-value*</td><td>% below</td><td>% within</td><td>% above</td><td>p-value</td></tr><tr><td>CD3+</td><td>56-86</td><td>0.95</td><td>98.1</td><td>0.95</td><td>0.3</td><td>0.0</td><td>100.0</td><td>0.0</td><td>0.2</td></tr><tr><td>CD4+</td><td>33-58</td><td>7.6</td><td>78.3</td><td>14.1</td><td>0.0001</td><td>1.8</td><td>80.7</td><td>17.5</td><td>0.0001</td></tr><tr><td>CD8+</td><td>13-39</td><td>12.3</td><td>81.1</td><td>6.6</td><td>0.0001</td><td>8.8</td><td>86.0</td><td>5.2</td><td>0.004</td></tr><tr><td>CD19+</td><td>5-22</td><td>9.4</td><td>89.6</td><td>1.0</td><td>0.0001</td><td>1.7</td><td>96.5</td><td>1.8</td><td>0.9</td></tr><tr><td>CD 16+56+</td><td>5-26</td><td>0.0</td><td>91.5</td><td>8.5</td><td>0.0001</td><td>3.5</td><td>94.7</td><td>1.8</td><td>0.8</td></tr></table> |
efac52e090d9ad205c56686d62df4ff44bb8b937b3d8584f0cfcdc7fa097fccf.png | complex | <table><tr><td>Residue</td><td>p<i>K</i>a</td><td>Buried (%)</td><td colspan="2">Desolvation effects</td><td colspan="2">Hydrogen bond</td><td>Coulombic interaction</td><td>Atoms cofactor</td></tr><tr><td></td><td></td><td></td><td>Regular</td><td>RE</td><td>Side chain</td><td>Backbone</td><td></td><td></td></tr><tr><td>Tyr345 G</td><td>11.99</td><td>56 %</td><td>0.90 438</td><td>0.00 0</td><td>0.21 Asp315 G</td><td></td><td>–0.02 Arg3180.90 Asp315</td><td></td></tr><tr><td><i> Asp315</i></td><td><i>2.63</i></td><td>97</td><td><i>3.82 554</i></td><td><i>1.17 0</i></td><td><i>–1.60 His313 G</i><i>–0.85 Lys319 G</i><i>–0.20 Tyr342 G</i><i>–0.21 Tyr345 G</i></td><td><i>–0.08 Tyr345 G</i></td><td><i>–0.10 Arg318</i><i>–0.32 His316</i><i>–1.13 His313</i><i>–1.66 Lys319</i></td><td>=>N3 FAD</td></tr><tr><td><i> Arg318</i></td><td>11.00</td><td>92</td><td><i>–1.93 540</i></td><td><i>0.00 0</i></td><td></td><td></td><td><i>0.21 Glu45</i><i>0.04 Asp296</i><i>0.10 Asp315</i><i>0.02 Tyr345</i></td><td>=>N10 FAD=>N10 FAD</td></tr><tr><td>Tyr292</td><td>9.95</td><td>38</td><td>1.12 387</td><td>0.00 0</td><td>–0.77 Lys285 G</td><td>0.00 Xxx0 X</td><td>0.08 Asp281 G0.10 Asp290–0.01 Lys102–0.58 Lys285</td><td></td></tr><tr><td><i> Asp281</i></td><td>3.91</td><td>32</td><td><i>1.47 370</i></td><td><i>0.13 0</i></td><td></td><td><i>–0.18 Asp281 G</i><i>–0.19 Lys285 G</i></td><td><i>-0.08 Lys279</i><i>0.02 Glu 339</i></td><td></td></tr><tr><td><i> Asp290</i></td><td><i>3.07</i></td><td>3</td><td><i>0.53 290</i></td><td><i>0.02 0</i></td><td><i>–0.85 Lys102 G</i></td><td><i>–0.02 Asp290 G</i></td><td><i>–0.03 Lys 285</i><i>–0.38 Lys102</i></td><td></td></tr><tr><td><i> Lys102</i></td><td>11.07</td><td>0</td><td><i>–0.67 268</i></td><td><i>0.00 0</i></td><td><i>0.85 Asp290 G</i></td><td></td><td><i>0.01 Tyr292 G</i><i>0.38 Asp 290</i></td><td></td></tr><tr><td><i> Lys285</i></td><td><i>10.17</i></td><td>45</td><td><i>–2.04 406</i></td><td><i>0.00 0</i></td><td><i>0.77 Tyr 292 G</i></td><td></td><td><i>0.34 Asp281 GX</i><i>0.03 Asp290 G</i><i>0.58 Tyr292</i></td><td></td></tr><tr><td>Tyr213</td><td>11.13</td><td>23</td><td>0.86 347</td><td>0.00 0</td><td></td><td></td><td>0.27 Asp352</td><td></td></tr><tr><td><i>Asp352</i></td><td><i>3.50</i></td><td>5</td><td><i>0.42 295</i></td><td><i>0.01 0</i></td><td></td><td><i>-0.52 Asp352 G</i><i>–0.09 Leu353 G</i></td><td><i>–0.02 Lys217</i><i>–0.10 Arg349</i></td><td></td></tr></table> |
d8ab1d6a0283898f3bb2a206ce46324abf6b7d6aff7a5a68d5191856026c18e6.png | complex | <table><tr><td>Component</td><td>Changes in SLE T cells</td><td>Reference</td></tr><tr><td colspan="3">TCRζ</td></tr><tr><td></td><td>Decreased TCRζ expression/phosphorylation</td><td>Grammatikos et al. (26), Kyttaris et al. (27), Pang et al. (29), and Takeuchi et al. (28)</td></tr><tr><td></td><td>3′ UTR variants leading to instable versions of TCRζ</td><td>Chowdhury et al. (30), Gorman et al. (31), and Tsuzaka et al. (32)</td></tr><tr><td colspan="3">Syk</td></tr><tr><td></td><td>Replaces canonical ZAP-70</td><td>Krishnan et al. (33) and Tanaka et al. (34)</td></tr><tr><td></td><td>More potent signal transduction</td><td>Tanaka et al. (34)</td></tr><tr><td></td><td>Increased expression: inability of CREMα to repress transcription</td><td>Ghosh et al. (35)</td></tr><tr><td colspan="3">Calcium signaling</td></tr><tr><td rowspan="2"></td><td>Increased recruitment of NFATc2 into the nucleus</td><td rowspan="2">Kyttaris et al. (36)</td></tr><tr><td>→ Elevated expression of CD154</td></tr><tr><td rowspan="2"></td><td>Enhanced nuclear import of CAMK IV</td><td rowspan="2">Juang et al. (37)</td></tr><tr><td>→ Elevated expression of CREMα</td></tr><tr><td colspan="3">Other signaling components</td></tr><tr><td></td><td>LAT displaced from lipid rafts</td><td>Abdoel et al. (38)</td></tr><tr><td></td><td>Aberrant phosphorylation of Erk</td><td>Cedeno et al. (39) and Yi et al. (40)</td></tr><tr><td colspan="3">Genes identified by GWAS</td></tr><tr><td rowspan="2"></td><td>UBASH3A</td><td>Diaz-Gallo et al. (41)</td></tr><tr><td>PP2AC</td><td>Katsiari et al. (42), and Tan et al. (43)</td></tr><tr><td rowspan="2"></td><td>TNFAIP3</td><td>Graham et al. (44)</td></tr><tr><td>SLAM</td><td>Morel et al. (45)</td></tr></table> |
61da956f4b0867655e15d6a7bff421854d9ab361336f0651015a1d46c49cd9c4.png | simple | <table><tr><td>Variable</td><td>Mean (SD)</td><td>Range</td></tr><tr><td>Age (years)</td><td>65.6 (9.5)</td><td>49 – 80</td></tr><tr><td>Duration of disease (years)</td><td>14.3 (5.7)</td><td>5 – 23</td></tr><tr><td>MDS-UPDRS-3</td><td>51.7 (15.8)</td><td>15 – 83</td></tr><tr><td>MDS-UPDRS-4</td><td>8.6 (6.4)</td><td>0 – 20</td></tr><tr><td>NMSS total</td><td>74.9 (28.9)</td><td>39 – 140</td></tr><tr><td>PDQ-8 total</td><td>37.3 (16.3)</td><td>12.5 – 65.6</td></tr><tr><td>HADS total</td><td>16.3 (6.6)</td><td>5 – 28</td></tr><tr><td>ACE-R total</td><td>90.1 (7.6)</td><td>73 – 100</td></tr></table> |
4e4a0c9bede704e8765099d9e8e33189338e9deada71d06bb813967ff2a08c8b.png | complex | <table><tr><td> </td><td colspan="5">Antibiotic class</td></tr><tr><td>Strains</td><td>Carb-apenem</td><td colspan="2">Cephalo-sporin</td><td>Aminogly-coside</td><td>Fluoro-quinolone</td></tr><tr><td>Antibiotics*</td><td>IPM</td><td>CFP</td><td>CAZ</td><td>GM</td><td>CIP</td></tr><tr><td>ATCC 27853</td><td>29</td><td>30</td><td>33</td><td>21</td><td>34</td></tr><tr><td>1</td><td>29</td><td>22</td><td>28</td><td>21</td><td>28</td></tr><tr><td>3</td><td>12</td><td>25</td><td>28</td><td>21</td><td>24</td></tr><tr><td>6</td><td>34</td><td>28</td><td>33</td><td>23</td><td>32</td></tr><tr><td>11</td><td>30</td><td>28</td><td>30</td><td>21</td><td>32</td></tr><tr><td>19</td><td>28</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>26</td><td>0</td><td>10</td><td>0</td><td>9</td><td>0</td></tr><tr><td>38</td><td>0</td><td>9</td><td>0</td><td>8</td><td>0</td></tr><tr><td>43a</td><td>9</td><td>0</td><td>0</td><td>16</td><td>0</td></tr><tr><td>47</td><td>21</td><td>12</td><td>0</td><td>12</td><td>0</td></tr></table> |
4d77cab7733fb1fa0310ab2a586e0bf494295172c07b52a2408f56022f489e8c.png | simple | <table><tr><td>Treatment</td><td>Urea (g)</td><td>ERP (g)</td><td>K source (g)</td></tr><tr><td>T0</td><td>0.00</td><td>0.00</td><td>0.00</td></tr><tr><td>T1</td><td>4.84</td><td>7.45</td><td>2.48 MOP</td></tr><tr><td>T2</td><td>3.24</td><td>4.95</td><td>53.02 RS humin</td></tr><tr><td>T3</td><td>3.58</td><td>5.67</td><td>68.90 RH humin</td></tr><tr><td>T4</td><td>3.86</td><td>6.36</td><td>63.22 SD humin</td></tr><tr><td>T5</td><td>3.94</td><td>6.48</td><td>43.39 EFB humin</td></tr><tr><td>T6</td><td>2.92</td><td>4.51</td><td>50.95 RS compost</td></tr><tr><td>T7</td><td>0.83</td><td>0.00</td><td>164.46 RH compost</td></tr><tr><td>T8</td><td>0.26</td><td>1.07</td><td>227.48 SD compost</td></tr><tr><td>T9</td><td>3.71</td><td>5.31</td><td>53.05 EFB compost</td></tr></table> |
64c5f596c099c685d8cb4276cda5b0c1f395f7d34d221ed2bd9c033fbb3a0eae.png | complex | <table><tr><td></td><td></td><td colspan="2"><underline>No. of patients (%)</underline></td><td></td></tr><tr><td>Variable</td><td>Total</td><td colspan="2"><i>KLK5</i>- negative <i>KLK5</i>- positive</td><td>p value</td></tr><tr><td>Menopausal status*</td><td></td><td></td><td></td><td></td></tr><tr><td>Pre/peri</td><td>54</td><td>22 (40.7)</td><td>32 (59.3)</td><td>0.005<sup>b</sup></td></tr><tr><td>Post</td><td>47</td><td>33 (70.2)</td><td>14 (29.8)</td><td></td></tr><tr><td>Grade<sup>c</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>I</td><td>3</td><td>1 (33.3)</td><td>2 (66.7)</td><td></td></tr><tr><td>II</td><td>30</td><td>21 (70.0)</td><td>9 (30.0)</td><td>0.34<sup>d</sup></td></tr><tr><td>III</td><td>34</td><td>25 (73.5)</td><td>9 (26.5)</td><td></td></tr><tr><td>TNM Tumor size</td><td></td><td></td><td></td><td></td></tr><tr><td><2 cm</td><td>26</td><td>17 (65.4)</td><td>9 (34.6)</td><td></td></tr><tr><td>2-5 cm</td><td>37</td><td>27 (73.0)</td><td>10 (27.0)</td><td>0.79<sup>d</sup></td></tr><tr><td>> 5 cm</td><td>4</td><td>3 (75.0)</td><td>1 (25.0)</td><td></td></tr><tr><td>ER status</td><td></td><td></td><td></td><td></td></tr><tr><td>Negative</td><td>16</td><td>7 (43.8)</td><td>9 (56.3)</td><td>0.028<sup>b</sup></td></tr><tr><td>Positive</td><td>51</td><td>39 (76.5)</td><td>12 (23.5)</td><td></td></tr><tr><td>PR status</td><td></td><td></td><td></td><td></td></tr><tr><td>Negative</td><td>24</td><td>15 (62.5)</td><td>9 (37.5)</td><td>0.42<sup>b</sup></td></tr><tr><td>Positive</td><td>43</td><td>31 (72.1)</td><td>12 (27.9)</td><td></td></tr></table> |
30f56805abd58f2d81ee3a7703587bfd25dbc1694aa991ed6bae4f1185d5c2c2.png | complex | <table><tr><td rowspan="2">Cross<i><sup>a</sup></i></td><td colspan="2">Genotype</td><td rowspan="2">Total</td></tr><tr><td><i>amhy</i><sup>+</sup> (%)</td><td><i>amhy<sup>−</sup></i> (%)</td></tr><tr><td>A</td><td>21 (46.7)</td><td>24 (53.3)</td><td>45</td></tr><tr><td>B</td><td>16 (35.6)</td><td>29 (64.4)</td><td>45</td></tr><tr><td>C</td><td>21 (51.2)</td><td>20 (49.8)</td><td>41</td></tr><tr><td>D</td><td>20 (52.6)</td><td>18 (47.4)</td><td>38</td></tr><tr><td>Total</td><td>78 (46.2)</td><td>91 (53.8)</td><td>169</td></tr></table> |
14ee8012d5ef9e6bb02268068f807058e19fa0774e7bd92dee90fb3e50182744.png | simple | <table><tr><td>Days</td><td>Scenario 1</td><td>Scenario 2</td><td>Scenario 3</td><td>Scenario 4</td><td>Scenario 5</td><td>Scenario 6</td><td>Scenario 7</td></tr><tr><td>1</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td>2</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td>3</td><td>●</td><td>● (± α h)</td><td>○</td><td>●</td><td>●1</td><td>●</td><td>●</td></tr><tr><td>4</td><td>●1</td><td>●1</td><td>●</td><td>●1</td><td>●1</td><td>○</td><td>● (+ 4 h)1</td></tr><tr><td>5</td><td>●1</td><td>●1</td><td>●</td><td>● (± β h)1</td><td>●1</td><td>●1</td><td>●1</td></tr><tr><td>6</td><td>●1</td><td>●1</td><td>●1</td><td>●1</td><td>○1</td><td>●1</td><td>●1</td></tr><tr><td><i>n</i></td><td>24</td><td>24</td><td>24</td><td>24</td><td>24</td><td>24</td><td>72</td></tr><tr><td><i>t</i> (h)</td><td>24</td><td>24</td><td>24</td><td>24</td><td>24</td><td>24</td><td>72 (-4)</td></tr><tr><td><i>ni</i> (X-ray)</td><td>70</td><td>52</td><td>24</td><td>60</td><td>69 (+24)</td><td>48</td><td>65</td></tr><tr><td>CTT (h)</td><td>70</td><td>52</td><td>24</td><td>60</td><td>93</td><td>48</td><td>61.4</td></tr></table> |
5686d3cd9733294da7854a046e1bd14fce8e019bab3a2b7a8dc7bded3226eb4e.png | simple | <table><tr><td> </td><td>Rest</td><td>Placebo</td><td>Fermented milk</td></tr><tr><td>Serum hsCRP (ng·mL<sup>-1</sup>)</td><td>88.9 ± 11.7</td><td>113.6 ± 22.1</td><td>79.3 ± 10.6</td></tr><tr><td>Serum TNF-α (pg·mL<sup>-1</sup>)</td><td>0.161 ± 0.002</td><td>0.166 ± 0.001</td><td>0.170 ± 0.004</td></tr><tr><td>Serum carbonyl protein (nmol·mg<sup>-1</sup>)</td><td>0.086 ± 0.003</td><td>0.089 ± 0.004</td><td>0.096 ± 0.003</td></tr><tr><td>Urine 8-OHdG (μg)</td><td>1.82 ± 0.16</td><td>1.70 ± 0.16</td><td>1.72 ± 0.19</td></tr></table> |
3afff9b1b73549442dbdb7e7b6feac82149edcceef581fb5a23155d4a836e48e.png | simple | <table><tr><td>Score</td><td><i>P</i> value</td><td>OR (95% CI)</td></tr><tr><td>HRD-LOH</td><td>0.069</td><td>3.0 (0.89, 9.8)</td></tr><tr><td>HRD-TAI</td><td>0.00016</td><td>5.8 (2.1, 16)</td></tr><tr><td>HRD-LST</td><td>0.00014</td><td>7.4 (2.4, 23)</td></tr></table> |
3793907e25386aa0d1c0ee267b584cae6664ceaee22987b4d3e49309ca4200f7.png | simple | <table><tr><td>Variable/domain</td><td>Personal</td><td>Social environment</td><td>Physical environment</td><td>Total score</td></tr><tr><td> </td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td></tr><tr><td>Age cluster</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Young</td><td>31.9 ± 8.3</td><td>8.7 ± 2.9</td><td>11.5 ± 3.6</td><td>52.2 ± 12.5</td></tr><tr><td>Middle age</td><td>32.5 ± 9.0</td><td>9.3 ± 2.8</td><td>12.0 ± 3.8</td><td>53.7 ± 13.2</td></tr><tr><td>elderly</td><td>32.8 ± 10.3</td><td>8.9 ± 2.8</td><td>12.1 ± 4.1</td><td>53.8 ± 15.1</td></tr><tr><td><i>p</i> value</td><td>0.667</td><td>0.059</td><td>0.294</td><td>0.417</td></tr><tr><td>Ethnicity</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Malay</td><td>34.1 ± 9.0<sup>a</sup></td><td>8.9 ± 2.7</td><td>11.8 ± 3.7</td><td>54.9 ± 13.3<sup>a</sup></td></tr><tr><td>Chinese</td><td>31.2 ± 8.9</td><td>9.1 ± 3.0</td><td>11.9 ± 3.8</td><td>52.1 ± 13.4</td></tr><tr><td><i>p</i> value</td><td><0.001*</td><td>0.350</td><td>0.689</td><td>0.007*</td></tr><tr><td>Marital status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Single</td><td>32.2 ± 7.7</td><td>8.4 ± 2.5</td><td>11.7 ± 3.5</td><td>52.2 ± 11.2</td></tr><tr><td>Married</td><td>32.4 ± 9.4</td><td>9.2 ± 2.9<sup>a</sup></td><td>11.9 ± 3.9</td><td>53.6 ± 13.9</td></tr><tr><td><i>p</i> value</td><td>0.717</td><td>0.002*</td><td>0.552</td><td>0.278</td></tr><tr><td>Employment status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Unemployed</td><td>32.3 ± 9.4</td><td>8.3 ± 2.6</td><td>12.2 ± 3.9</td><td>52.8 ± 13.8</td></tr><tr><td>Employed</td><td>32.5 ± 8.9</td><td>9.4 ± 2.9<sup>a</sup></td><td>11.7 ± 3.7</td><td>53.5 ± 13.2</td></tr><tr><td><i>p</i> value</td><td>0.826</td><td><0.001*</td><td>0.170</td><td>0.473</td></tr><tr><td>Educational level</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Primary</td><td>35.3 ± 9.4<sup>a</sup></td><td>9.4 ± 3.1</td><td>13.7 ± 4.1<sup>a</sup></td><td>58.5 ± 13.9<sup>a</sup></td></tr><tr><td>Secondary</td><td>33.0 ± 9.1<sup>a</sup></td><td>9.1 ± 2.9</td><td>12.0 ± 3.7<sup>b</sup></td><td>54.0 ± 13.4<sup>b</sup></td></tr><tr><td>Tertiary</td><td>30.3 ± 8.5<sup>b</sup></td><td>8.8 ± 2.7</td><td>11.0 ± 3.4<sup>c</sup></td><td>50.0 ± 12.3<sup>c</sup></td></tr><tr><td><i>p</i> value</td><td><0.001*</td><td>0.166</td><td><0.001*</td><td><0.001*</td></tr><tr><td>Monthly household income</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><RM1500</td><td>34.7 ± 9.8<sup>a</sup></td><td>8.9 ± 2.7</td><td>12.8 ± 4.0<sup>a</sup></td><td>56.4 ± 14.2<sup>a</sup></td></tr><tr><td>RM1500-RM3500</td><td>32.5 ± 8.6<sup>b</sup></td><td>9.2 ± 3.0</td><td>12.0 ± 3.8<sup>a</sup></td><td>53.6 ±13.0<sup>a</sup></td></tr><tr><td>>RM3500</td><td>30.5 ± 8.6<sup>c</sup></td><td>8.9 ± 2.8</td><td>11.0 ± 3.4<sup>b</sup></td><td>50.7 ± 12.7<sup>b</sup></td></tr><tr><td><i>p</i> value</td><td><0.001*</td><td>0.399</td><td><0.001*</td><td><0.001*</td></tr><tr><td>BMI</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Underweight</td><td>32.4 ± 10.0</td><td>9.0 ± 3.1</td><td>13.4 ± 3.8</td><td>54.8 ± 14.9</td></tr><tr><td>Normal</td><td>31.0 ± 9.0<sup>a</sup></td><td>8.8 ± 2.9<sup>a</sup></td><td>11.8 ± 3.9</td><td>51.5 ± 13.5<sup>a</sup></td></tr><tr><td>Overweight</td><td>33.1 ± 8.7<sup>b</sup></td><td>9.1 ± 2.8</td><td>11.6 ± 3.4</td><td>53.9 ± 12.8<sup>a</sup></td></tr><tr><td>Obese</td><td>36.3 ± 8.8<sup>c</sup></td><td>9.8 ± 2.7<sup>b</sup></td><td>12.4 ± 4.2</td><td>58.5 ± 13.3<sup>b</sup></td></tr><tr><td><i>p</i> value</td><td><0.001*</td><td>0.034*</td><td>0.073</td><td><0.001*</td></tr><tr><td>Waist circumference</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><90cm</td><td>31.2 ± 8.9</td><td>8.8 ± 3.0</td><td>12.0 ± 3.8</td><td>51.9 ± 13.4</td></tr><tr><td>≥90cm</td><td>33.7 ± 9.1<sup>a</sup></td><td>9.3 ± 2.8<sup>a</sup></td><td>11.8 ± 3.7</td><td>54.8 ± 13.3<sup>a</sup></td></tr><tr><td><i>p</i> value</td><td><0.001*</td><td>0.043*</td><td>0.546</td><td>0.003*</td></tr><tr><td>Physical activity</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Sedentary</td><td>38.2 ± 7.5<sup>a</sup></td><td>10.7 ± 2.4<sup>a</sup></td><td>13.4 ± 3.3<sup>a</sup></td><td>62.4 ± 10.1<sup>a</sup></td></tr><tr><td>Insufficiently active</td><td>32.5 ± 8.9<sup>b</sup></td><td>9.1 ± 2.8<sup>b</sup></td><td>12.0 ± 3.7<sup>b</sup></td><td>53.5 ± 13.0<sup>b</sup></td></tr><tr><td>Sufficiently active</td><td>30.8 ± 9.0<sup>c</sup></td><td>8.5 ± 2.8<sup>c</sup></td><td>11.4 ± 3.9<sup>b</sup></td><td>50.7 ± 13.8<sup>c</sup></td></tr><tr><td><i>p</i> value</td><td><0.001*</td><td><0.001*</td><td><0.001*</td><td><0.001*</td></tr></table> |
269d139b82039ad93345153cc61dd96b0d9897f961ff26e4a220c0679bc4fec7.png | complex | <table><tr><td rowspan="3">Feature</td><td colspan="4">Wheeled Vehicle</td><td rowspan="3">Tracked Vehicle</td><td rowspan="3">Low-Altitude Helicopter</td></tr><tr><td>Car</td><td>Truck</td><td>SUV</td><td>Van</td></tr><tr><td>Weight (kg)</td><td>1,425</td><td>6,800</td><td>1,635</td><td>1,713</td><td>40,200</td><td>3,850</td></tr><tr><td>Number of Cylinders</td><td>4</td><td>6</td><td>4</td><td>5</td><td>10</td><td>8</td></tr><tr><td>Engine Capacity</td><td>78</td><td>170</td><td>110</td><td>140</td><td>3,240</td><td>1,468</td></tr></table> |
d75d773b0633e1783147c1aa2feaf360795d107229eec0b41311285ce45e5ee8.png | complex | <table><tr><td> </td><td colspan="2">Recognition rates (%)</td><td> </td></tr><tr><td>Method</td><td colspan="2">No. of training samples</td><td>Average recognition rates (%)</td></tr><tr><td> </td><td>3</td><td>4</td><td> </td></tr><tr><td>GWT</td><td>79.65</td><td>82.5</td><td>81.1</td></tr><tr><td>KDCV</td><td>69.5</td><td>75</td><td>72.25</td></tr><tr><td>GWT-LDA</td><td>82.76</td><td>85.33</td><td>84.1</td></tr><tr><td>GWT-KDCV (RBF)</td><td>81</td><td>82.50</td><td>81.75</td></tr><tr><td>GWT-KDCV (Cosine)</td><td>83</td><td>85</td><td>84.5</td></tr><tr><td>GWT-KDCV (RBF, low-energized)</td><td>88.5</td><td>91.5</td><td>90</td></tr><tr><td>GWT-KDCV (Cosine, low-energized)</td><td>92.5</td><td>95.75</td><td>94.1</td></tr></table> |
82374917162a25264e08275f2a39e1cf6c6c7477b8c72f463a4eab48ed82fe33.png | simple | <table><tr><td>Sample</td><td>Added (μM)</td><td>Found (μM)</td><td>RSD (%)<sup>a</sup></td><td>Recovery(%)</td></tr><tr><td>1</td><td>50.0</td><td>51.2</td><td>3.1</td><td>102.5</td></tr><tr><td>2</td><td>100.0</td><td>98.5</td><td>3.2</td><td>98.5</td></tr><tr><td>3</td><td>150.0</td><td>151.9</td><td>2.8</td><td>101.3</td></tr></table> |
8faeb68973e070d98fda435486e4688c6211accb27dac9a3b815a852c1f24e82.png | complex | <table><tr><td>Technique</td><td>Description</td><td>Metrics</td><td>Evidence of changes in trauma</td><td>Population</td></tr><tr><td rowspan="4">Time domain</td><td rowspan="4">Estimation of variability using statistics and measures of central tendency [3]</td><td>HRVi</td><td>↓ predicts mortality, ICH, adrenal insufficiency [11, 15, 19–22, 36]</td><td>ICU</td></tr><tr><td>Uncoupling</td><td>↑ reflects acidosis, coagulopathy, MOSF, AI, severe TBI, ↑ ICP, predicts mortality [6, 9, 12, 22]</td><td>ICU</td></tr><tr><td>SDNN</td><td>↓ predicts TBI, mortality, acidosis, LSI [16, 23]</td><td>PrehospitalERICU</td></tr><tr><td>RMSSD</td><td>↓ reflects TBI, hemorrhage, mortality [23, 28, 47]</td><td>ERICU</td></tr><tr><td rowspan="4">Frequency domain</td><td rowspan="4">Calculation of power (amplitude) of contributing frequencies to an underlying signal [18]</td><td>TP</td><td>↓ reflects ↑ICP, TBI, prolonged neurologic recovery, need for LSI, mortality, brain death [10, 28, 43]</td><td>ICUOutpatient</td></tr><tr><td>LF</td><td>↓ reflects ↑ICP, TBI, hemorrhage, need for LSI, mortality, brain; ↑ reflects ↑CI, HR, MAP death [4, 10, 27, 28, 37, 43, 48, 49].</td><td>ERICU</td></tr><tr><td>HF</td><td>↓ reflects trauma, ↑ICP, need for LSI, hemorrhage, brain death, and mortality [10, 37, 43, 47, 50, 51]</td><td>Prehospital</td></tr><tr><td>LF/HF</td><td>↑ reflects ↑ICP, ↓CPP; ↓ reflects brain death, mortality, hemorrhage, ↓GCS, poor neurologic outcome [5, 7, 10, 27, 48, 51]</td><td>PrehospitalICU</td></tr><tr><td rowspan="8">Entropy</td><td rowspan="8">Measurement of overall disorder, randomness, or irregularity of a physiologic signal [18]</td><td>MSE</td><td>↓ predicts mortality [13, 35, 36, 45]</td><td>ICU</td></tr><tr><td>ApEn</td><td>↓ reflects trauma, burn, hemorrhage, brain death, and ↑ICP, MOSF, predicts mortality; ↑ reflects resuscitation [8, 14, 25, 29, 34, 37, 52]</td><td>Prehospital</td></tr><tr><td>SampEn</td><td>↓ reflects trauma, mortality, burn, and hemorrhage;↑ reflects resuscitation; predicts LSI [8, 25, 43]</td><td>Prehospital</td></tr><tr><td>FDCL</td><td>↓ reflects hemorrhage; ↑ reflects resuscitation;↓ predicts LSI [17]</td><td>Prehospital</td></tr><tr><td>FDDA</td><td>↓ reflects need for LSI, hemorrhage, mortality [8, 25, 43]</td><td>Prehospital</td></tr><tr><td>DFA</td><td>↓ reflects mortality; predicts LSI [8, 25, 43]</td><td>Prehospital</td></tr><tr><td>SOD</td><td>↑ reflects need for LSI, mortality [8, 25, 43]</td><td>Prehospital</td></tr><tr><td>StatAv</td><td>↓ reflects mortality [25]</td><td>Prehospital</td></tr></table> |
3e1c448ab71d95ca59c07271cd6ee9070d62396b86b005e58e24c28675dac476.png | simple | <table><tr><td>Probe Name</td><td>Gene</td><td>Log Rank <i>P</i>-value for 2 groups (median split)</td><td>Log Rank <i>P</i>-value for 3 groups (tertile split)</td></tr><tr><td>merck_NM_001216_at_CA9</td><td>CA9</td><td>0.03<sup>*</sup></td><td>0.01<sup>*</sup></td></tr><tr><td>merck2_DQ892208_at_CA9</td><td>CA9</td><td>0.04<sup>*</sup></td><td>0.02<sup>*</sup></td></tr><tr><td>merck_NM_001218_s_at_CA12</td><td>CA12</td><td><0.01<sup>*</sup></td><td>0.02<sup>*</sup></td></tr><tr><td>merck_AK096845_a_at_CA12</td><td>CA12</td><td><0.0001<sup>*</sup></td><td><0.01<sup>*</sup></td></tr><tr><td>merck2_BC087838_at_CA12</td><td>CA12</td><td><0.01<sup>*</sup></td><td><0.01<sup>*</sup></td></tr><tr><td>merck_NM_001017978_s_at_CXorf61</td><td>CXorf61</td><td><0.01<sup>*</sup></td><td>0.08</td></tr><tr><td>merck_BX538327_at_DSG3</td><td>DSG3</td><td>0.53</td><td>0.10</td></tr><tr><td>merck_NM_001944_a_at_DSG3</td><td>DSG3</td><td>0.33</td><td>0.65</td></tr><tr><td>merck2_M76482_at_DSG3</td><td>DSG3</td><td>0.48</td><td>0.88</td></tr><tr><td>merck_NM_001447_at_FAT2</td><td>FAT2</td><td>0.78</td><td>0.49</td></tr><tr><td>merck_NM_023915_s_at_GPR87</td><td>GPR87</td><td>0.15</td><td>0.04<sup>*</sup></td></tr><tr><td>merck_NM_032551_s_at_KISS1R</td><td>KISS1R</td><td>0.94</td><td>0.88</td></tr><tr><td>merck_NM_014400_at_LYPD3</td><td>LYPD3</td><td>0.03<sup>*</sup></td><td><0.01<sup>*</sup></td></tr><tr><td>merck_NM_014331_at_SLC7A11</td><td>SLC7A11</td><td><0.01<sup>*</sup></td><td>0.02<sup>*</sup></td></tr><tr><td>merck_AI924527_a_at_TMPRSS4</td><td>TMPRSS4</td><td>0.75</td><td>0.46</td></tr><tr><td>merck2_NM_001083947_at_TMPRSS4</td><td>TMPRSS4</td><td>0.41</td><td>0.74</td></tr><tr><td>merck2_NM_183247_a_at_TMPRSS4</td><td>TMPRSS4</td><td>0.93</td><td>0.57</td></tr></table> |
33a48bf36ea60f432550a93b8a78624d280ddeb361ae4b0c969a1156bbd306dd.png | complex | <table><tr><td></td><td colspan="6">Weeks postinfection</td></tr><tr><td></td><td colspan="2">4</td><td colspan="2">7</td><td colspan="2">10</td></tr><tr><td></td><td>Control rats</td><td>Infected rats</td><td>Control rats</td><td>Infected rats</td><td>Control rats</td><td>Infected rats</td></tr><tr><td>TAS mol/g tissue</td><td>110.6 ± 6.5</td><td>93.5 ± 7.3a</td><td>108.2 ± 6.9</td><td>91.4 ± 7.5a</td><td>112.5 ± 6.1</td><td>98.8 ± 7.7a</td></tr></table> |
f1c51f990ae5e8f422bdb63977a7789933b11d6d2c326e7fae74cea008284a28.png | simple | <table><tr><td>KEGG category</td><td>Distinct ECs</td><td>ECs found in the data (% abundance)</td><td>N° of matches</td></tr><tr><td><i>Energy metabolism</i></td><td><i>173</i></td><td><i>92 (53.5%)</i></td><td><i>3,857</i></td></tr><tr><td>Carbon fixation</td><td>25</td><td>21 (84%)</td><td>986</td></tr><tr><td>Methane metabolism</td><td>33</td><td>12 (36.4%)</td><td>202</td></tr><tr><td>Nitrogen metabolism</td><td>58</td><td>30 (51.7%)</td><td>739</td></tr><tr><td>Oxidative phosphorylation</td><td>17</td><td>09 (52.9%)</td><td>972</td></tr><tr><td>Photosynthesis</td><td>03</td><td>01 (33%)</td><td>168</td></tr><tr><td>Redutive carboxylate cycle (CO2 fixation)</td><td>13</td><td>13 (100%)</td><td>531</td></tr><tr><td>Sulfur metabolism</td><td>30</td><td>12 (40%)</td><td>267</td></tr><tr><td><i>Biodegradation of Xenobiotics</i></td><td><i>217</i></td><td><i>66 (30.4%)</i></td><td><i>2,495</i></td></tr><tr><td>DDT degradation</td><td>10</td><td>03 (30%)</td><td>74</td></tr><tr><td>1,2-Dichloroethane degradation</td><td>05</td><td>04 (80%)</td><td>85</td></tr><tr><td>1,4-Dichlorobenzene degradation</td><td>22</td><td>06 (27.3%)</td><td>74</td></tr><tr><td>2,4-Dichlorobenzoate degradation</td><td>29</td><td>03 (10.3%)</td><td>18</td></tr><tr><td>3-Chloroacrylic acid degradation</td><td>04</td><td>04 (100%)</td><td>185</td></tr><tr><td>Atrazine degradation</td><td>12</td><td>04 (33.3%)</td><td>24</td></tr><tr><td>Benzoate degradation via CoA ligation</td><td>45</td><td>23 (51%)</td><td>994</td></tr><tr><td>Benzoate degradation via hydroxylation</td><td>50</td><td>18 (36%)</td><td>158</td></tr><tr><td>Biphenyl degradation</td><td>13</td><td>03 (23.1%)</td><td>71</td></tr><tr><td>Caprolactam degradation</td><td>22</td><td>10 (45.5%)</td><td>131</td></tr><tr><td>Carbazole degradation</td><td>11</td><td>01 (9.1%)</td><td>03</td></tr><tr><td>Ethylbenzene degradation</td><td>09</td><td>03 (33.3%)</td><td>207</td></tr><tr><td>Fluorene degradation</td><td>13</td><td>03(23.1%)</td><td>64</td></tr><tr><td>Naphthalene and anthracene degradation</td><td>21</td><td>03 (14.3%)</td><td>188</td></tr><tr><td>Styrene degradation</td><td>21</td><td>09 (42.9%)</td><td>73</td></tr><tr><td>Tetrachloroethene degradation</td><td>07</td><td>01 (14.3%)</td><td>57</td></tr><tr><td>Toluene and xylene degradation</td><td>22</td><td>07 (31.8%)</td><td>32</td></tr><tr><td>γ-Hecachlorocyclohexane degradation</td><td>24</td><td>07 (29.2%)</td><td>57</td></tr><tr><td><i>Carbohydrate metabolism</i></td><td><i>576</i></td><td><i>284 (49.3%)</i></td><td><i>9,901</i></td></tr><tr><td>Aminosugars metabolism</td><td>41</td><td>25 (61%)</td><td>589</td></tr><tr><td>Ascorbate and aldarate metabolism</td><td>43</td><td>18 (41.9%)</td><td>367</td></tr><tr><td>Butanoate metabolism</td><td>53</td><td>34 (64.2%)</td><td>1,802</td></tr><tr><td>C5-Branched dibasic acid metabolism Fructose</td><td>17</td><td>03 (17.6%)</td><td>126</td></tr><tr><td>and mannose metabolism</td><td>66</td><td>28 (42.4%)</td><td>591</td></tr><tr><td>Galactose metabolism</td><td>37</td><td>19 (51.4%)</td><td>529</td></tr><tr><td>Glycolysis/Gluconeogenesis</td><td>42</td><td>29 (69%)</td><td>858</td></tr><tr><td>Glyoxylate and dicarboxylate metabolism</td><td>58</td><td>30 (51.7%)</td><td>676</td></tr><tr><td>Inositol metabolism</td><td>09</td><td>07 (77.8%)</td><td>90</td></tr><tr><td>Inositol phosphate metabolism</td><td>30</td><td>05 (16.4%)</td><td>34</td></tr><tr><td>Nucleotide sugars metabolism</td><td>34</td><td>18 (52.9%)</td><td>517</td></tr><tr><td>Pentose and glucuronate interconversions</td><td>56</td><td>27(48.2%)</td><td>229</td></tr><tr><td>Pentose phosphate pathway</td><td>39</td><td>31 (79.5%)</td><td>846</td></tr><tr><td>Propanoate metabolism</td><td>49</td><td>34 (69.4%)</td><td>1032</td></tr><tr><td>Pyruvate metabolism</td><td>65</td><td>39 (60%)</td><td>1,117</td></tr><tr><td>Starch and sucrose metabolism</td><td>73</td><td>33 (45.2%)</td><td>498</td></tr></table> |
75d8cb03f14d51e5cd4c38f8f9584678da755f83f2062a32af2d656e89e4b3ab.png | simple | <table><tr><td></td><td>AGG</td><td>AGGPEN</td><td>DMEAN</td><td>DMODE</td><td>SBA</td></tr><tr><td>Cronbach’s α</td><td>0.75</td><td>0.76</td><td>0.79</td><td>0.77</td><td>0.68</td></tr><tr><td>min</td><td>31.0</td><td>24.6</td><td>31.3</td><td>18.3</td><td>49.1</td></tr><tr><td>max</td><td>83.2</td><td>85.0</td><td>85.9</td><td>86.8</td><td>83.9</td></tr><tr><td>range</td><td>52.2</td><td>60.4</td><td>54.6</td><td>68.5</td><td>34.8</td></tr><tr><td>median</td><td>66.9</td><td>65.3</td><td>71.3</td><td>67.0</td><td>72.6</td></tr><tr><td>mean</td><td>63.9</td><td>62.5</td><td>66.8</td><td>62.8</td><td>71.2</td></tr><tr><td>SD</td><td>11.77</td><td>13.17</td><td>12.95</td><td>16.30</td><td>7.72</td></tr><tr><td>CI (mean, 0.95)</td><td>3.15</td><td>3.53</td><td>3.47</td><td>4.37</td><td>2.07</td></tr></table> |
203e2973a43fba2f86ae0a5d547e456c11cf2042dd81d059cf35f53a3455a386.png | complex | <table><tr><td>Name</td><td>Descriptions</td><td>Reference</td></tr><tr><td colspan="3"><i>Bacterial strains</i></td></tr><tr><td><i>E. coli</i> BL21 (DE3)</td><td>F-, <i>dcm</i>, <i>ompT</i>, <i>gal</i>, <i>lon</i>, <i>hsd</i>S<sub>B</sub> (rB<sup>−</sup>, mB<sup>−</sup>), λ (DE3[<i>lac</i>I, <i>lac</i>UV5-T7 gene 1, <i>ind</i>1, <i>sam</i>7,<i>nin</i>5])</td><td>Lab stock</td></tr><tr><td>J3</td><td><i>E. coli</i> BL21 (DE3) harboring <i>rbcLS</i>-pET30a + (M259T)</td><td>[15]</td></tr><tr><td>JB</td><td><i>E. coli</i> BL21 (DE3) harboring both P<sub>BAD</sub>-his6-<i>prkA</i>-pACYC184 and <i>rbcLS</i>-pET30a + (M259T)</td><td>[15]</td></tr><tr><td>MZ</td><td><i>E. coli</i> BL21 (DE3) Δ<i>zwf</i></td><td>[16]</td></tr><tr><td>MZL</td><td>MZ, Δ<i>ldh</i></td><td>This study</td></tr><tr><td>MZLF</td><td>MZL, Δ<i>frd</i></td><td>This study</td></tr><tr><td>MZLF1</td><td>MZLF harboring P<sub>BAD</sub>-his6-<i>prkA</i>-pACYC184</td><td>This study</td></tr><tr><td>MZLF3</td><td>MZLF harboring <i>rbcLS</i>-pET30a + (M259T)</td><td>This study</td></tr><tr><td>MZLFB</td><td>MZLF harboring both P<sub>BAD</sub>-his6-<i>prkA</i>-pACYC184 and <i>rbcLS</i>-pET30a + (M259T)</td><td>This study</td></tr><tr><td colspan="3"><i>Plasmids</i></td></tr><tr><td>pKD46</td><td><i>araC</i>, <i>bla</i>, <i>oriR101</i>, <i>repA</i>101 (Ts), <i>araC</i>-<i>P</i><sub><i>araB</i></sub>-<i>γ</i>-<i>β</i>-<i>exo</i> (encode λ Red recombinases), temperature-conditional replicon</td><td>[30]</td></tr><tr><td>pkD13</td><td><i>bla</i>, FRT-<i>kan</i>-FRT</td><td>[30]</td></tr><tr><td>pCP20</td><td><i>FLP</i><sup>+</sup>, λ <i>c</i>I857<sup>+</sup>,λ P<sub>R</sub> Pep<sup>ts</sup>, <i>bla</i>, <i>catF</i></td><td>[31]</td></tr><tr><td>P<sub>BAD</sub>-his6-<i>prkA</i>-pA CYC184</td><td>Recombinant plasmid carries <i>prkA</i> gene (derived from <i>Synechococcus</i> PCC7492) for the overexpresion of phosphoribulokinase (PrkA) under the control of P<sub>BAD</sub></td><td>[13]</td></tr><tr><td><i>rbcLS</i>-pET30a + (M259T)</td><td>Recombinant plasmid carries engineered <i>rbcLS</i> gene (originated from <i>Synechococcus</i> PCC6301) for the overexpresion of engineered Rubisco (M259T) under the control of P<sub>T7</sub></td><td>[13]</td></tr><tr><td><i>rbcLS</i>-pET30a + (M259T, K198G)</td><td>Recombinant plasmid carries engineered <i>rbcLS</i> gene (originated from <i>Synechococcus</i> PCC6301) for the overexpresion of engineered Rubisco (M259T and K198G) under the control of P<sub>T7</sub></td><td>This study</td></tr><tr><td><i>rbcLS</i>-pET30a + (M259T, K198G, D200G, E201G)</td><td>Recombinant plasmid carries engineered <i>rbcLS</i> gene (originated from <i>Synechococcus</i> PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, D200G, and E201G) under the control of PT7</td><td>This study</td></tr><tr><td><i>rbcLS</i>-pET30a + (M259T, K198G, K172G)</td><td>Recombinant plasmid carries engineered <i>rbcLS</i> gene (originated from <i>Synechococcus</i> PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, and K172G) under the control of P<sub>T7</sub></td><td>This study</td></tr><tr><td><i>rbcLS</i>-pET30a + (M259T, K198G, K331G)</td><td>Recombinant plasmid carries engineered <i>rbcLS</i> gene (originated from <i>Synechococcus</i> PCC6301) for the overexpresion of engineered Rubisco (M259T, K198G, and K331G) under the control of P<sub>T7</sub></td><td>This study</td></tr></table> |
c05d099ac7c03c278fc7df8a028de1b500c9bc1cf85b45a3bbf3259bbd2d6ae7.png | simple | <table><tr><td>Dosimetry Parameter</td><td>Mean % Diff</td><td><i>t </i>test score</td><td>P value</td></tr><tr><td>D90</td><td>0.61</td><td>1.74</td><td>0.0842</td></tr><tr><td>V100</td><td>0.07</td><td>0.68</td><td>0.4990</td></tr><tr><td>V150</td><td>3.67</td><td>4.95</td><td>0.0001</td></tr><tr><td>V200</td><td>20.47</td><td>11.30</td><td>0.0001</td></tr></table> |
63b165668e4a8e6d3e89451a6aaa2ec24eb14ac3642e5f7019db69fe773c9b50.png | complex | <table><tr><td></td><td colspan="3">GPA score</td><td colspan="3">SIR score</td><td colspan="2">BSBM score</td></tr><tr><td></td><td>0</td><td>0.5</td><td>1</td><td>0</td><td>1</td><td>2</td><td>0</td><td>1</td></tr><tr><td>Age</td><td>≥60</td><td>51-59</td><td>≤50</td><td>≥60</td><td>51-59</td><td>≤50</td><td colspan="2">NA</td></tr><tr><td>KPS</td><td><70</td><td>70-80</td><td>90-100</td><td>≤50</td><td>60-70</td><td>>70</td><td>50-70</td><td>80-100</td></tr><tr><td>Control of primary cancer</td><td colspan="3">NA</td><td>PD</td><td>PR-SD</td><td>CR-NED</td><td>No</td><td>Yes</td></tr><tr><td>Volume of the largest BM (cc)</td><td colspan="3">NA</td><td>>13</td><td>5-13</td><td><5</td><td colspan="2">NA</td></tr><tr><td>No. of BM</td><td>>3</td><td>2-3</td><td>1</td><td>≥3</td><td>2</td><td>1</td><td colspan="2">NA</td></tr><tr><td>EC metastasis</td><td>(+)</td><td></td><td>(−)</td><td colspan="3">NA</td><td>(+)</td><td>(−)</td></tr></table> |
f3c25fd288d5ceafd84a44bce75f8814085f8f31e835b702541b51119bdf0287.png | complex | <table><tr><td>Screening tool</td><td>Positive result</td><td>Sensitivity</td><td>Specificity</td><td>Study Populations</td></tr><tr><td> </td><td> </td><td>(95% CI)</td><td>(95% CI)</td><td> </td></tr><tr><td>AUDIT-C</td><td>≥ 4 (men)</td><td>86 (80-92) men</td><td>89 (85-93) men</td><td rowspan="2">Primary care [24]</td></tr><tr><td>(3 items)*</td><td>≥ 3 (women)</td><td>73 (66-79) women</td><td>91 (89-93) women</td></tr><tr><td>Quantity-Frequency</td><td>Exceeding recommended</td><td>88 (83-94) men</td><td>84 (80-89) men</td><td rowspan="2">Primary care [24]</td></tr><tr><td>(3 items)*</td><td>drinking limits</td><td>68 (61-75) women</td><td>91 (89-93) women</td></tr><tr><td>Heavy-drinking day</td><td>Any heavy days (≥ 4 drinks women, ≥ 5 drinks men)</td><td>83 (71-90) men</td><td>72 (61-81) men</td><td>Primary care [27]</td></tr><tr><td>past year (1 item)</td><td> </td><td>81 (64-91) women</td><td>84 (76-89) women</td><td> </td></tr></table> |
065c9af54a6727b156f3e1ec89a037ce61f97b843956ef7f49dae21e5cce107a.png | simple | <table><tr><td></td><td>SCD (n = 60)</td><td>HbAA (n = 59)</td><td>p</td></tr><tr><td>Age* (years)</td><td>7.92 (6.98-9.98)</td><td>5.45 (4.67-6.35)</td><td>0.001</td></tr><tr><td>Weight (kg)</td><td>23.18 (19.11)</td><td>20.54 (8.34)</td><td>0.077</td></tr><tr><td>Temperature (°C)</td><td>37.90 (1.12)</td><td>38.62 (1.12)</td><td>0.001</td></tr><tr><td>Jaundice (n)</td><td>42 (79.2 %)</td><td>4 (6.7 %)</td><td>< 0.001</td></tr><tr><td>Spleen size (cm)</td><td>1.27 (2.73)</td><td>0.20 (0.81)</td><td>0.008</td></tr><tr><td>Liver size (cm)</td><td>3.42 (4.70)</td><td>0.43 (1.32)</td><td>< 0.001</td></tr><tr><td>Parasite density* (/μL)</td><td>1,197 (645-2221)</td><td>11,774 (5256-26375)</td><td>0.0006</td></tr><tr><td>Haemoglobin (g/dL)</td><td>6.56 (2.22)</td><td>9.71 (2.16)</td><td><0.0001</td></tr><tr><td>WBC (10<sup>9</sup>/L)</td><td>23.95 (18.45)</td><td>10.21 (5.92)</td><td><0.0001</td></tr><tr><td>Platelet count (10<sup>9</sup>/L)</td><td>254.8 (133.9)</td><td>154.9 (106.1)</td><td><0.0002</td></tr></table> |
7f78508af9a32260c98d2419aa47f0a4f0088bb4bf0021672a0e7d0ecdc76fcc.png | simple | <table><tr><td>Treatment</td><td>ctb</td><td>csb</td><td>del</td><td>r</td><td>cf</td><td>ra</td><td>Total aberrations<sup>a</sup></td></tr><tr><td>Solvent control : Tween-80 (1%)</td><td>-</td><td>1</td><td>-</td><td>6</td><td>6</td><td>-</td><td>13 ± 0.58</td></tr><tr><td>Methyl methansulfonate (MMS)</td><td>-</td><td>16</td><td>-</td><td>17</td><td>12</td><td>-</td><td>44 ± 3.06</td></tr><tr><td>TOF enriched extract</td><td>-</td><td>3</td><td>-</td><td>3</td><td>3</td><td>-</td><td>9 ± 1.53</td></tr><tr><td>Aqueous extract</td><td>-</td><td>4</td><td>-</td><td>4</td><td>2</td><td>-</td><td>10 ± 0.62</td></tr><tr><td>Methanolic extract</td><td>-</td><td>-</td><td>-</td><td>3</td><td>11</td><td>-</td><td>14 ± 0,58</td></tr><tr><td>Solvent control : Tween-80 (5%)</td><td>-</td><td>-</td><td>-</td><td>10</td><td>7</td><td>-</td><td>17 ± 1.15</td></tr><tr><td>Ethyl acetate extract</td><td>-</td><td>2</td><td>-</td><td>12</td><td>5</td><td>-</td><td>19 ± 1.53</td></tr></table> |
7d623e4f34d353c39a88251578b8a35379c9c5bc21f7bddd2eeeca9cfdd7bceb.png | simple | <table><tr><td>Ingredient</td><td>Control Cream</td><td>Test Cream</td></tr><tr><td>Xyliance</td><td>4%</td><td>4%</td></tr><tr><td>Kendi oil</td><td>0.5%</td><td>0.5%</td></tr><tr><td>Phenoxyethanol</td><td>0.5%</td><td>0.5%</td></tr><tr><td>Aqua</td><td>QS</td><td>QS</td></tr><tr><td><i>Rhodosorus marinus</i> extract/Dexamethasone</td><td></td><td>1% or 3%/0.2%</td></tr></table> |
6d667854e57aeb5bc50b31f7c29d119c3dc1da28fb025c15b6cab2d0b0eabfc4.png | complex | <table><tr><td colspan="2"></td><td colspan="4">Days after SIV infection</td></tr><tr><td colspan="2">Animal #</td><td>Day 14</td><td>Day 18</td><td>Day 21</td><td>Day 28</td></tr><tr><td>206</td><td>blood</td><td>100%<sup>a </sup>(17/17)<sup>b</sup></td><td>14.3% (3/21)</td><td>0% (0/26)</td><td>ND<sup>c</sup></td></tr><tr><td></td><td>milk</td><td>100% (30/30)</td><td>87.5% (28/32)</td><td>17.4% (4/23)</td><td>0% (0/17)</td></tr><tr><td>257</td><td>blood</td><td>100% (29/29)</td><td>90.9% (20/22)</td><td>38.5% (10/26)</td><td>0% (0/20)</td></tr><tr><td></td><td>milk</td><td>100% (21/21)</td><td>100% (30/30)</td><td>54.5% (12/22)</td><td>0% (0/31)</td></tr><tr><td>402</td><td>blood</td><td>100% (28/28)</td><td>12.5% (3/24)</td><td>7.7% (2/26)</td><td>ND</td></tr><tr><td></td><td>milk</td><td>100% (18/18)</td><td>31.0% (9/29)</td><td>16.7% (1/6)</td><td>0% (0/32)</td></tr><tr><td>403</td><td>blood</td><td>100% (29/29)</td><td>54.2% (13/24)</td><td>9.4% (3/32)</td><td>ND</td></tr><tr><td></td><td>milk</td><td>100% (23/23)</td><td>47.6% (10/21)</td><td>17.4% (4/23)</td><td>0% (0/31)</td></tr></table> |
f3b3b8959ac00e6f33c7bcf7a5816c185004e2ea848fb2bef4e3d175e4389461.png | simple | <table><tr><td>Parameters</td><td>Respondents</td><td>Mbarali district (%)</td><td>Momba district (%)</td><td>p value</td></tr><tr><td>Age of household head (years)</td><td></td><td></td><td></td><td></td></tr><tr><td> 15-30</td><td>120</td><td>1.7</td><td>11.7</td><td>0.013</td></tr><tr><td> 31-45</td><td>120</td><td>52.5</td><td>45</td><td></td></tr><tr><td> 46-60</td><td>120</td><td>35</td><td>29.2</td><td></td></tr><tr><td> >60</td><td>120</td><td>10.8</td><td>14.2</td><td></td></tr><tr><td>Experience of keeping cattle (years)</td><td></td><td></td><td></td><td></td></tr><tr><td> <5</td><td>120</td><td>1.7</td><td>11.7</td><td>0.005</td></tr><tr><td> 5-10</td><td>120</td><td>35</td><td>37.5</td><td></td></tr><tr><td> >10</td><td>120</td><td>63.3</td><td>50.8</td><td></td></tr><tr><td>Level of education of the household head</td><td></td><td></td><td></td><td></td></tr><tr><td> No formal education</td><td>120</td><td>0.8</td><td>25</td><td><0.0001</td></tr><tr><td> Primary education</td><td>120</td><td>80</td><td>65</td><td></td></tr><tr><td> Secondary education</td><td>120</td><td>19.2</td><td>9.2</td><td></td></tr><tr><td> College education</td><td>120</td><td>0</td><td>0.8</td><td></td></tr><tr><td>Land owned by the household</td><td></td><td></td><td></td><td></td></tr><tr><td> <5 acres</td><td>120</td><td>3.3</td><td>15.8</td><td>0.01</td></tr><tr><td> 5-10 acres</td><td>120</td><td>36.7</td><td>34.2</td><td></td></tr><tr><td> 11-50 acres</td><td>120</td><td>57.5</td><td>46.7</td><td></td></tr><tr><td> >50 acres</td><td>120</td><td>2.5</td><td>3.3</td><td></td></tr><tr><td>Number of cattle raised by the household</td><td></td><td></td><td></td><td></td></tr><tr><td> <10 cattle</td><td>120</td><td>3.3</td><td>34.2</td><td><0.0001</td></tr><tr><td> 10-50 cattle</td><td>120</td><td>68.3</td><td>59.2</td><td></td></tr><tr><td> >50 cattle</td><td>120</td><td>28.3</td><td>6.7</td><td></td></tr></table> |
8c5ef62119480c2b53b4158ab2af366881b851236f1ea5af5eb92e1e5f8b8cc5.png | simple | <table><tr><td></td><td>Delusions of guilt</td><td>Delusions of grandiosity</td><td>Persecutory delusions</td><td>Somatic delusions</td><td>None of these delusional types</td></tr><tr><td>Schizophrenia</td><td>2 (1.7%)</td><td>7 (6.0%)</td><td>33 (28.4%)</td><td>7 (6.0%)</td><td>76 (75.5%)</td></tr><tr><td>Delusional disorder</td><td>0</td><td>1 (2.4%)</td><td>21 (50.0%)</td><td>3 (7.1%)</td><td>19 (45.2%)</td></tr><tr><td>Schizoaffective disorder, manic type</td><td>0</td><td>2 (22.2)</td><td>1 (11.1%)</td><td>0</td><td>6 (66.7%)</td></tr><tr><td>Schizoaffective disorder, mixed type</td><td>0</td><td>0</td><td>1 (14.3%)</td><td>1 (14.3%)</td><td>5 (71.4%)</td></tr><tr><td>Schizoaffective disorder, depressive type</td><td>2 (8.3%)</td><td>0</td><td>4 (16.7%)</td><td>0</td><td>18 (75.0%)</td></tr><tr><td>Bipolar I disorder, current episode manic</td><td>0</td><td>16 (21.6)</td><td>7 (9.5%)</td><td>1 (1.4%)</td><td>54 (73.0%)</td></tr><tr><td>Bipolar I disorder, current episode mixed</td><td>1 (9.1%)</td><td>1 (9.1%)</td><td>3 (27.3%)</td><td>1 (9.1%)</td><td>7 (63.6%)</td></tr><tr><td>Bipolar disorder, current episode depressed with psychotic features</td><td>6 (42.9%)</td><td>0</td><td>6 (42.9%)</td><td>4 (28.6%)</td><td>3 (21.4%)</td></tr><tr><td>Major depressive disorder with psychotic features</td><td>24 (47.1%)</td><td>0</td><td>3 (5.9%)</td><td>6 (11.8%)</td><td>22 (43.1%)</td></tr><tr><td>Between-group differences</td><td>MDD > all other groups except BD and BM (<i>p</i> < 0.001)BD > all other groups except BM and SAD (<i>p</i> < 0.01)</td><td>M > MDD and SC (<i>p</i> < 0.001)SAMA > MDD (<i>p</i> < 0.05)</td><td>SC (<i>p</i> < 0.05), DD (<i>p</i> < 0.01), and BD (<i>p</i> < 0.05) > MDDDD (<i>p</i> < 0.01) and BD (<i>p</i> < 0.05) > M</td><td>BD > M (<i>p</i> < 0.01)</td><td></td></tr></table> |
fbc9d12ff8ed66f37dd2dfde6e3cbf3f423b26eaa17516c2a47b9c36164332fb.png | complex | <table><tr><td>Item</td><td>Common themes</td><td>Groups</td><td>Quotes</td></tr><tr><td rowspan="4">Description and causes of fatigue.</td><td>Overwhelming physical tiredness with consequences on difficulties to move</td><td>Common in all groups: RA, AxSpA and fibromyalgia</td><td>I feel that my body is broken and every movement is as if I was moving a mountain</td></tr><tr><td>The need to rest more</td><td>RA and fibromyalgia</td><td>In the morning when I see my kids, I already feel tired and I even feel that I did not want to wake up</td></tr><tr><td>A sense of freezing of the body</td><td>AxSpA</td><td>When I have fatigue, my body is wooden and I move with difficulty</td></tr><tr><td>A toxin in the body</td><td>RA and AxSpA</td><td>It is toxic in my body, everything becomes difficult</td></tr><tr><td>Fatigue and pain</td><td>Close association between fatigue and pain</td><td>Common in all groups: RA, AxSpA and fibromyalgia</td><td></td></tr><tr><td rowspan="3">Daily patterns of fatigue</td><td>Fatigue is more in the morning</td><td>AxSpA</td><td>When I get up I feel that I am very tired and I wait for one hour to be able to move</td></tr><tr><td>Fatigue is more in the evening</td><td>RA, AxSpA</td><td>At the end of the day when I have finished my tasks I feel that my body is broken</td></tr><tr><td>No special daily patterns</td><td>Fibromyalgia</td><td></td></tr><tr><td rowspan="3">Consequences of fatigue</td><td>Fatigue affected physical activity to the extent that participants did their work only minimally</td><td>Common in all groups: RA, AxSpA and fibromyalgia</td><td>I do important things only</td></tr><tr><td>Social activities became limited to the close family and to very important occasions.</td><td>RA and fibromyalgia (female only)</td><td>I go to weddings and condolence gatherings only, because of my fatigue</td></tr><tr><td>Fatigue affected leisure activities markedly</td><td>RA and fibromyalgia</td><td>I forget what leisure means</td></tr><tr><td></td><td>A difficulty in reaching the place of work</td><td>Common in all groups: RA, AxSpA and fibromyalgia</td><td>I can hardly walk to my work though it is only about 30 min</td></tr><tr><td></td><td>Women told their husbands to marry again</td><td>RA and fibromyalgia</td><td>I asked my husband to marry again, he needs a healthy woman and I am too tired</td></tr><tr><td></td><td>A decrease in male sexual activity</td><td>AxSpA</td><td>I get fatigued easily and this is a problem for my sexual life</td></tr><tr><td>Coping strategies</td><td>Dividing big tasks into smaller multiple tasks</td><td>Common in all groups: RA, AxSpA and fibromyalgia</td><td></td></tr><tr><td></td><td>Getting help from family members</td><td>RA</td><td>My mother and sisters help me to complete my daily tasks</td></tr></table> |
6f69d06325289bd77b28e0ab7e5bcfbaa086a6387a610a63b0b4fa6f4e29f850.png | simple | <table><tr><td>Cluster</td><td>TRANSFAC Annotations</td><td></td><td></td><td></td></tr><tr><td>A</td><td>V$POU3F2_02</td><td></td><td></td><td></td></tr><tr><td></td><td>V$ISRE_01: interferon-stimulated response element</td><td></td><td></td><td></td></tr><tr><td></td><td>V$DEAF1_01</td><td></td><td></td><td></td></tr><tr><td></td><td>V$E2F1_Q3_01</td><td></td><td></td><td></td></tr><tr><td></td><td>V$MAZR_01: MAZ related factor</td><td></td><td></td><td></td></tr><tr><td></td><td>V$KROX_Q6</td><td></td><td></td><td></td></tr><tr><td></td><td>V$E2F1DP1_01: E2F-1:DP-1 heterodimer</td><td></td><td></td><td></td></tr><tr><td></td><td>V$HNF1_Q6</td><td></td><td></td><td></td></tr><tr><td></td><td>V$E2F_Q3_01</td><td></td><td></td><td></td></tr><tr><td></td><td>V$E2F1_Q6: E2F-1</td><td></td><td></td><td></td></tr><tr><td>Cluster</td><td>Common GO Parent Node</td><td>Gene Ontology</td><td>GO Level</td><td>GO Name</td></tr><tr><td>B</td><td>signal transduction [4] GO:0007165</td><td>GO:0007264</td><td>6</td><td>small GTPase mediated signal transduction</td></tr><tr><td></td><td></td><td>GO:0007165</td><td>4</td><td>signal transduction</td></tr><tr><td></td><td></td><td>GO:0007242</td><td>5</td><td>intracellular signaling cascade</td></tr><tr><td>C</td><td>programmed cell death [5] GO:0012501</td><td>GO:0006917</td><td>8</td><td>induction of apoptosis</td></tr><tr><td></td><td></td><td>GO:0012502</td><td>7</td><td>induction of programmed cell death</td></tr><tr><td></td><td></td><td>GO:0043068</td><td>6</td><td>positive regulation of programmed cell death</td></tr><tr><td></td><td></td><td>GO:0043065</td><td>7</td><td>positive regulation of apoptosis</td></tr><tr><td></td><td></td><td>GO:0050794</td><td>3*</td><td>regulation of cellular process</td></tr><tr><td></td><td></td><td>GO:0016265</td><td>3*</td><td>death</td></tr><tr><td></td><td></td><td>GO:0008219</td><td>4*</td><td>cell death</td></tr><tr><td></td><td></td><td>GO:0012501</td><td>5</td><td>programmed cell death</td></tr><tr><td></td><td></td><td>GO:0006915</td><td>6</td><td>apoptosis</td></tr><tr><td></td><td></td><td>GO:0043067</td><td>5</td><td>regulation of programmed cell death</td></tr><tr><td></td><td></td><td>GO:0042981</td><td>6</td><td>regulation of apoptosis</td></tr><tr><td>D</td><td>response to stress [4] GO:0006950</td><td>GO:0006950</td><td>4</td><td>response to stress</td></tr><tr><td>E</td><td>macromolecule metabolic process [4] GO:0043170</td><td>GO:0006493</td><td>9</td><td>O-linked glycosylation</td></tr><tr><td></td><td></td><td>GO:0043170</td><td>4</td><td>macromolecule metabolism</td></tr><tr><td></td><td></td><td>GO:0044260</td><td>5</td><td>cellular macromolecule metabolism</td></tr><tr><td></td><td></td><td>GO:0019222</td><td>4*</td><td>regulation of metabolism</td></tr><tr><td>F</td><td>transcription [6] GO:0006350</td><td>GO:0006350</td><td>6</td><td>transcription</td></tr><tr><td></td><td></td><td>GO:0045449</td><td>6</td><td>regulation of transcription</td></tr><tr><td></td><td></td><td>GO:0019219</td><td>5*</td><td>regulation of nucleo-base, -side, -tide and nucleic acid metabolism</td></tr><tr><td></td><td></td><td>GO:0006355</td><td>7</td><td>regulation of transcription, DNA-dependent</td></tr><tr><td></td><td></td><td>GO:0006351</td><td>7</td><td>transcription, DNA-dependent</td></tr><tr><td>G</td><td>cell cycle process [6] GO:0022402</td><td>GO:0000082</td><td>7</td><td>G1/S transition of mitotic cell cycle</td></tr><tr><td></td><td></td><td>GO:0000132</td><td>11</td><td>mitotic spindle orientation</td></tr><tr><td>H</td><td>mevalonate transport [8] GO:0015728</td><td>GO:0015728</td><td>8</td><td>mevalonate transport</td></tr></table> |
84c3b88c483dc469538b58669da2cd72e3845c73bc0726f13892607a22d33f41.png | simple | <table><tr><td>Age in years (Mean ± SD)</td><td>30.4 ± 7.7</td><td></td><td></td><td></td></tr><tr><td>Gender# (%)</td><td>Female2,144 (44.5%)</td><td>Male2,675 (55.5%)</td><td></td><td></td></tr><tr><td>Residency Year# of residents</td><td>R1 = 1,638</td><td>R2 = 1,578</td><td>R3 = 1,152</td><td>>R3 = 685</td></tr></table> |
27b9752ddc36a7a3ca471cc1b0a01b44eef74a8fe793517f99fa3297edaa4496.png | complex | <table><tr><td>Variables</td><td>Total (<i>n</i> = 2068)</td><td>Survivors (<i>n</i> = 1464)</td><td>Non-survivors (<i>n</i> = 604)</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>62.3 ± 0.4</td><td>59.3 ± 0.5</td><td>69.3 ± 0.5</td><td><0.001</td></tr><tr><td>Male (<i>n</i> (%))</td><td>1177 (56.9%)</td><td>817 (55.8%)</td><td>360 (59.6%)</td><td>0.113</td></tr><tr><td>Weight (kg)</td><td>82.4 ± 0.5</td><td>83.4 ± 0.6</td><td>79.8 ± 0.9</td><td><0.001</td></tr><tr><td colspan="5">Reasons for admission</td></tr><tr><td> Cardiac disorder (<i>n</i> (%))</td><td>627 (30.3%)</td><td>405 (27.6%)</td><td>222 (36.8%)</td><td><0.001</td></tr><tr><td> Cerebral disorder (<i>n</i> (%))</td><td>367 (17.7%)</td><td>282 (19.3%)</td><td>85 (14.1%)</td><td>0.005</td></tr><tr><td> Gastrointestinal disorder (<i>n</i> (%))</td><td>177 (8.5%)</td><td>130 (8.9%)</td><td>47 (7.8%)</td><td>0.417</td></tr><tr><td> Respiratory disorder (<i>n</i> (%))</td><td>345 (16.7%)</td><td>226 (15.4%)</td><td>119 (19.7%)</td><td>0.018</td></tr><tr><td> Sepsis (<i>n</i> (%))</td><td>1010 (48.8%)</td><td>661 (45.1%)</td><td>349 (57.8%)</td><td><0.001</td></tr><tr><td colspan="5">Type of ICU</td></tr><tr><td> Medical (<i>n</i> (%))</td><td>706 (34.1%)</td><td>474 (32.3%)</td><td>232 (38.4%)</td><td>0.009</td></tr><tr><td> Cardiac (<i>n</i> (%))</td><td>547 (26.4%)</td><td>346 (23.6%)</td><td>201 (33.2%)</td><td><0.001</td></tr><tr><td> Surgical (<i>n</i> (%))</td><td>356 (17.2%)</td><td>266 (18.2%)</td><td>90 (14.9%)</td><td>0.073</td></tr><tr><td> AKI incidence (<i>n</i> (%))</td><td>464 (22.4%)</td><td>249 (17.0%)</td><td>215 (35.6%)</td><td><0.001</td></tr><tr><td> Maximum SOFA score (median (IQR))</td><td>6 (3–8)</td><td>5 (3–8)</td><td>7 (4–10)</td><td><0.001</td></tr><tr><td> Fluid balance (ml/kg/48 hours)</td><td>–21.4 ± 0.4</td><td>–-21.5 ± 0.5</td><td>–20.9 ± 0.7</td><td>0.231</td></tr><tr><td> Fluid intake (ml/kg/48 hours)</td><td>52.2 ± 0.6</td><td>53.7 ± 0.7</td><td>48.3 ± 1.0</td><td><0.001</td></tr><tr><td> Urine output (ml/kg/48 hours)</td><td>65.3 ± 0.7</td><td>67.4 ± 0.8</td><td>60.1 ± 1.3</td><td><0.001</td></tr><tr><td> Diuretics (<i>n</i> (%))</td><td>778 (37.6%)</td><td>489 (33.4%)</td><td>289 (47.8%)</td><td><0.001</td></tr><tr><td> Blood products (<i>n</i> (%))</td><td>490 (23.7%)</td><td>300 (20.5%)</td><td>190 (31.2%)</td><td><0.001</td></tr></table> |
bbac883f1e7ac23ca920471ffef8dfae9db39e1dce0171e85aea1e6b63755b44.png | simple | <table><tr><td>Neonate causes</td><td>Level 1</td><td>Level 2A</td><td>Level 2B</td></tr><tr><td>Birth asphyxia</td><td>461</td><td>0</td><td>0</td></tr><tr><td>Congenital malformation</td><td>250</td><td>0</td><td>0</td></tr><tr><td>Meningitis (serious infection)</td><td>6</td><td>0</td><td>0</td></tr><tr><td>Pneumonia (serious infection)</td><td>84</td><td>5</td><td>0</td></tr><tr><td>Preterm delivery (<33 weeks gestational age [GA]) without respiratory distress syndrome (RDS)</td><td>353</td><td>0</td><td>0</td></tr><tr><td>Preterm delivery (with or without RDS) and sepsis</td><td>75</td><td>1</td><td>0</td></tr><tr><td>Preterm delivery (without RDS) and birth asphyxia</td><td>89</td><td>0</td><td>0</td></tr><tr><td>Preterm delivery (without RDS) and sepsis and birth asphyxia</td><td>34</td><td>0</td><td>0</td></tr><tr><td>Respiratory distress syndrome (33-36 weeks GA)</td><td>13</td><td>0</td><td>0</td></tr><tr><td>Respiratory distress syndrome (<33 weeks GA)</td><td>97</td><td>0</td><td>0</td></tr><tr><td>Sepsis (serious infection)</td><td>127</td><td>1</td><td>0</td></tr><tr><td>Sepsis with local bacterial infection</td><td>32</td><td>1</td><td>0</td></tr><tr><td>Stillbirth</td><td>1,001</td><td>1</td><td>0</td></tr><tr><td>Tetanus</td><td>4</td><td>0</td><td>0</td></tr></table> |
e120d913d7f4fb3680a014dc3486ef8f265d1619956ca66b9bbcbd60840f90cd.png | simple | <table><tr><td>Clinical group</td><td>Age at diagnosis(mean and range)</td><td>Preexisting cardiovascular disease/hypertension</td><td>Preexisting type II diabetes</td><td>Smoker/exsmoker </td><td>Mean follow-up time posttreatment (years)</td><td>Mean time to onset of Grade 3 proctitis (range) </td></tr><tr><td>Control</td><td>69 (60–77)</td><td>8/20</td><td>3/20</td><td>8/20</td><td>6</td><td>N/A</td></tr><tr><td>Radiosensitive</td><td>73 (68–76)</td><td>6/10</td><td>1/10</td><td>4/10</td><td>7</td><td>21 months(9–41 months)</td></tr></table> |
cc4a3d085955389b8ea4fd34b6b62d6695c3a22f3d6b4577c50d847e3b83bd6e.png | complex | <table><tr><td rowspan="2">Group</td><td colspan="3">Protein length (aa)</td><td colspan="3">Exon number</td><td colspan="3">Exon length (nt)</td></tr><tr><td>Mean</td><td>Median</td><td>K</td><td>Mean</td><td>Median</td><td>K</td><td>Mean</td><td>Median</td><td>K</td></tr><tr><td>Alveolata</td><td>535</td><td>364</td><td>e</td><td>3.6</td><td>2</td><td>i</td><td>449</td><td>161</td><td>h</td></tr><tr><td>Amoebozoa</td><td>463</td><td>351</td><td>f</td><td>3.1</td><td>2</td><td>j</td><td>448</td><td>192</td><td>f</td></tr><tr><td>Chlorophyta</td><td>490</td><td>369</td><td>e</td><td>5.4</td><td>3</td><td>g</td><td>270</td><td>139</td><td>j</td></tr><tr><td>Choanoflagellida</td><td>648</td><td>459</td><td>b</td><td>8.2</td><td>6</td><td>b</td><td>237</td><td>113</td><td>m</td></tr><tr><td>Cryptophyta</td><td>435</td><td>316</td><td>h</td><td>6.5</td><td>5</td><td>c</td><td>199</td><td>82</td><td>n</td></tr><tr><td>Excavata</td><td>471</td><td>334</td><td>g</td><td>1.1</td><td>1</td><td>m</td><td>1330</td><td>935</td><td>a</td></tr><tr><td>Fungi</td><td>462</td><td>381</td><td>d</td><td>3.3</td><td>2</td><td>k</td><td>421</td><td>195</td><td>e</td></tr><tr><td>Haptophyta</td><td>367</td><td>294</td><td>i</td><td>3.7</td><td>3</td><td>h</td><td>295</td><td>164</td><td>g</td></tr><tr><td>Ichthyosporea</td><td>637</td><td>494</td><td>a</td><td>4.8</td><td>4</td><td>d</td><td>398</td><td>152</td><td>i</td></tr><tr><td>Metazoa</td><td>595</td><td>439</td><td>c</td><td>10.1</td><td>7</td><td>a</td><td>176</td><td>126</td><td>l</td></tr><tr><td>Nucleariida</td><td>690</td><td>499</td><td>a</td><td>4.8</td><td>4</td><td>e</td><td>429</td><td>216</td><td>c</td></tr><tr><td>Rhodophyta</td><td>411</td><td>334</td><td>g</td><td>1.9</td><td>1</td><td>n</td><td>665</td><td>330</td><td>b</td></tr><tr><td>Stramenopila</td><td>467</td><td>356</td><td>f</td><td>3.5</td><td>2</td><td>l</td><td>399</td><td>196</td><td>d</td></tr><tr><td>Streptophyta</td><td>436</td><td>363</td><td>f</td><td>5.7</td><td>4</td><td>f</td><td>230</td><td>128</td><td>k</td></tr></table> |
af363ffc2ee7dec9180c8818fef089e9cf2ae2ccde73841a86a9771f674b9d10.png | simple | <table><tr><td>Model</td><td>Bayes factor</td></tr><tr><td>40° Head orientation</td><td></td></tr><tr><td>Body orientation + hemifield</td><td>1</td></tr><tr><td>All other models</td><td>>100</td></tr><tr><td>20° Head orientation</td><td></td></tr><tr><td>Body orientation + hemifield</td><td>1</td></tr><tr><td>Body orientation * hemifield</td><td>22</td></tr><tr><td>All other models</td><td>>100</td></tr></table> |
d4a0378ac6bfe5c45a272439ceab3c0a6272aa27c5480287dd1aebdcc2ef02fb.png | complex | <table><tr><td> </td><td colspan="2">UEBMI</td><td colspan="2">URBMI</td></tr><tr><td> </td><td>Insured</td><td>Uninsured</td><td>Insured</td><td>Uninsured</td></tr><tr><td>Dependent variable</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Outpatient visit rate (%)</td><td>13.02</td><td>7.69</td><td>12.74</td><td>7.93</td></tr><tr><td> Inpatient visit rate (%)</td><td>6.11</td><td>5.52</td><td>4.68</td><td>2.99</td></tr><tr><td>Need variables</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Female</td><td>47.3</td><td>50.5</td><td>58.5</td><td>58.5</td></tr><tr><td> 45-59</td><td>34.1</td><td>36.7</td><td>23.5</td><td>23.0</td></tr><tr><td> 60+</td><td>16.8</td><td>15.0</td><td>16.4</td><td>16.5</td></tr><tr><td> Health status</td><td>79.2</td><td>80.2</td><td>81.5</td><td>81.9</td></tr><tr><td> Illness</td><td>12.9</td><td>12.8</td><td>12.3</td><td>10.2</td></tr><tr><td> Chronic disease</td><td>16.6</td><td>17.0</td><td>18.7</td><td>16.0</td></tr><tr><td>Control variables</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Annual personal expenditure</td><td>7192</td><td>7322</td><td>6840</td><td>7026</td></tr><tr><td> Married</td><td>82.6</td><td>81.9</td><td>63.5</td><td>61.5</td></tr><tr><td> Other married status</td><td>8.5</td><td>8.3</td><td>10.8</td><td>11.6</td></tr><tr><td> Commercial health insurance</td><td>5.1</td><td>4.3</td><td>4.7</td><td>4.0</td></tr><tr><td> Household population</td><td>3.5</td><td>3.6</td><td>3.5</td><td>3.5</td></tr><tr><td> Distance to the nearest health institution</td><td>10.0</td><td>8.8</td><td>9.8</td><td>9.5</td></tr></table> |
c858a3b9ca30821bf483d315ef0470a26b7fa0fafd7def9bc6498ef55b2022bd.png | simple | <table><tr><td>Classification</td><td> </td><td>BMI (kg/m<sup>2</sup>)</td></tr><tr><td>Underweight (A)</td><td>Thinness class III</td><td>< 16.00</td></tr><tr><td> </td><td>Thinness class II</td><td>16.00-16.99</td></tr><tr><td> </td><td>Thinness class I</td><td>17.00-18.49</td></tr><tr><td>Normal (B)</td><td>Eutrophia</td><td>18.50-22.99</td></tr><tr><td> </td><td> </td><td>23.00-24.99</td></tr><tr><td>Overweight (C)</td><td>Pre-obesity</td><td>25.00-27.49</td></tr><tr><td> </td><td> </td><td>27.50-29.99</td></tr><tr><td>Obesity (D)</td><td>Obesity class I</td><td>30.00-32.49</td></tr><tr><td> </td><td> </td><td>32.50-34.99</td></tr><tr><td> </td><td>Obesity class II</td><td>35.00-37.49</td></tr><tr><td> </td><td> </td><td>38.00-39.99</td></tr><tr><td> </td><td>Obesity class III</td><td>≥ 40.00</td></tr></table> |
d84c116f44e4e7a0a748315e986aa86f05a6e131018d2235352fa7dac3f29248.png | complex | <table><tr><td> </td><td colspan="5">Principal Components</td></tr><tr><td> </td><td>PC1</td><td>PC2</td><td>PC3</td><td>PC4</td><td>PC5</td></tr><tr><td>BMI</td><td>0,80</td><td>0,20</td><td>−0,23</td><td>0,20</td><td>−0,28</td></tr><tr><td>Waist circumference</td><td>0,75</td><td>0,23</td><td>−0,39</td><td>0,18</td><td>−0,15</td></tr><tr><td>Systolic blood pressure</td><td>0,72</td><td>−0,21</td><td>0,03</td><td>0,39</td><td>0,38</td></tr><tr><td>Diastolic blood pressure</td><td>0,56</td><td>−0,38</td><td>0,03</td><td>0,35</td><td>0,54</td></tr><tr><td>Fasting plasma glucose</td><td>0,19</td><td>−0,15</td><td>−0,31</td><td>−0,59</td><td>0,36</td></tr><tr><td>Insulin</td><td>0,62</td><td>0,35</td><td>−0,32</td><td>−0,17</td><td>−0,11</td></tr><tr><td>Total cholesterol</td><td>−0,03</td><td>−0,95</td><td>0,00</td><td>−0,04</td><td>−0,23</td></tr><tr><td>Triglycerides</td><td>0,45</td><td>−0,42</td><td>−0,20</td><td>−0,44</td><td>−0,07</td></tr><tr><td>HDL cholesterol</td><td>−0,55</td><td>−0,24</td><td>0,41</td><td>0,20</td><td>−0,09</td></tr><tr><td>LDL cholesterol</td><td>0,05</td><td>−0,88</td><td>−0,12</td><td>0,02</td><td>−0,22</td></tr><tr><td>C-reactive protein</td><td>0,50</td><td>−0,05</td><td>0,23</td><td>0,30</td><td>−0,37</td></tr><tr><td>FCD</td><td>−0,29</td><td>−0,13</td><td>−0,63</td><td>0,14</td><td>−0,22</td></tr><tr><td>RBCV</td><td>−0,58</td><td>0,01</td><td>−0,65</td><td>0,24</td><td>0,10</td></tr><tr><td>RBCV<sub>max</sub></td><td>−0,67</td><td>−0,15</td><td>−0,51</td><td>0,27</td><td>0,14</td></tr><tr><td>TRBCV<sub>max</sub></td><td>0,52</td><td>−0,36</td><td>0,01</td><td>−0,06</td><td>0,05</td></tr><tr><td>Proportion of total variation</td><td>29%</td><td>16.5%</td><td>12%</td><td>8%</td><td>7%</td></tr></table> |
1aad367d6835021d6b0225c386e569327708d78ffdf98438cb2ce3fd4b953c8e.png | complex | <table><tr><td>CATEGORY</td><td>ISSUES</td><td>EXAMPLES</td></tr><tr><td rowspan="2">Human resources</td><td>Teachers</td><td>“Some people hate school because teachers are terrible, they are not teaching and do not know how to teach.”</td></tr><tr><td>Managers</td><td>“Managers do not care about our quality of life.”</td></tr><tr><td>Moral abuse</td><td>Residents and teachers</td><td>“There are arrogant teachers.”</td></tr><tr><td rowspan="2">Demandings</td><td rowspan="2">Personal, familiar, institutional, and social</td><td>“The least I can do is to push myself as much as I can do.”</td></tr><tr><td>“Pressure in the medical program is big.”</td></tr><tr><td>Eating habits</td><td>Inadequate eating habits</td><td>“I learned from a resident to put lots of sugar in my coffee to curb the hunger.”</td></tr><tr><td>Financial resources</td><td>Financial dependence</td><td>“You cannot work during the program; I feel bad for being dependent on my parents.”</td></tr><tr><td>Lack of care with own health</td><td>Students adopt unhealthy life</td><td>“You see many medical students getting sick, being down, neglecting one's own body, unable to reflect on these things.”</td></tr><tr><td>Sleep</td><td>Sleep privacy</td><td>“I want, I need to sleep. I cannot do more shifts and study.”</td></tr><tr><td>Time</td><td>Demands of the program</td><td>“I think excessive workload decreases quality of life. You have class every day and then you have to study but you also have many other things in your life.”</td></tr><tr><td> </td><td> </td><td>“In the program there’s a lack of quality of life. Lack of time to lose, to think about life, plans, dreams.”</td></tr></table> |
29ad941560135682e79c3cf24f16181d735f108f9df8ff3c29725855083bba3f.png | complex | <table><tr><td>Variables</td><td><i>n</i></td><td colspan="3">Survival Status</td><td>Univariate</td><td colspan="2">Multivariate</td></tr><tr><td></td><td></td><td>1-Year(<i>n</i>)</td><td>2-Year(<i>n</i>)</td><td>Median survival (months)</td><td><i>P</i></td><td>RR</td><td><i>P</i></td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Male</td><td>51</td><td>24.2</td><td>4.4</td><td>7.8 ± 1.6</td><td></td><td>1</td><td></td></tr><tr><td> Female</td><td>33</td><td>25.6</td><td>11.0</td><td>6.7 ± 0.5</td><td>0.862</td><td>1.054</td><td>0.845</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> ≤60 years old</td><td>41</td><td>33.1</td><td>5.5</td><td>7.8 ± 1.6</td><td></td><td>1</td><td></td></tr><tr><td> >60 years old</td><td>43</td><td>16.5</td><td>8.2</td><td>6.7 ± 0.8</td><td>0.844</td><td>1.451</td><td>0.153</td></tr><tr><td>Clinical symptoms</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Asymptomatic</td><td>15</td><td>21.8</td><td>6.7</td><td>6.7 ± 0.5</td><td></td><td>1</td><td></td></tr><tr><td> Symptomatic</td><td>69</td><td>66.7</td><td>19</td><td>13.1 ± 1.1</td><td>0.001</td><td>3.923</td><td>< 0.001</td></tr><tr><td>Diameter (cm)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> ≤5</td><td>13</td><td>53.8</td><td>23.1</td><td>13.3 ± 2.8</td><td></td><td>1</td><td></td></tr><tr><td> 5-10</td><td>39</td><td>15.0</td><td>3.0</td><td>6.8 ± 0.5</td><td></td><td>2.476</td><td>0.025</td></tr><tr><td> ≥10</td><td>32</td><td>23.6</td><td>3.9</td><td>5.2 ± 0.4</td><td>0.013</td><td>3.165</td><td>0.011</td></tr><tr><td>Intrahepatic lesions</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Solitary</td><td>63</td><td>26.6</td><td>7.1</td><td>6.8 ± 1.0</td><td></td><td>1</td><td></td></tr><tr><td> Multiple nodules</td><td>21</td><td>18.5</td><td>6.2</td><td>5.2 ± 0.7</td><td>0.604</td><td>1.794</td><td>0.050</td></tr><tr><td>Tumor types</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Peripheral ICC</td><td>57</td><td>20.8</td><td>6.2</td><td>6.7 ± 1.0</td><td></td><td>1</td><td></td></tr><tr><td> Central ICC</td><td>27</td><td>31.9</td><td>8.0</td><td>6.8 ± 2.5</td><td>0.843</td><td>1.663</td><td>0.079</td></tr><tr><td>LN metastases</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Asynchronous</td><td>13</td><td>69.2</td><td>15.4</td><td>14.2 ± 2.3</td><td></td><td>1</td><td></td></tr><tr><td> Synchronous</td><td>71</td><td>15.5</td><td>5.2</td><td>5.9 ± 0.7</td><td>0.002</td><td>1.794</td><td>0.025</td></tr><tr><td>CA19-9 (U/L)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> ≤37</td><td>13</td><td>36.9</td><td>18.5</td><td>7.8 ± 2.4</td><td></td><td>1</td><td></td></tr><tr><td> 37-600</td><td>26</td><td>32.6</td><td>4.1</td><td>9.6 ± 1.4</td><td></td><td>1.639</td><td>0.232</td></tr><tr><td> ≥600</td><td>45</td><td>16.4</td><td>5.5</td><td>5.5 ± 0.7</td><td>0.307</td><td>1.343</td><td>0.451</td></tr><tr><td>EBRT</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>35</td><td>38.5</td><td>9.6</td><td>9.5 ± 1.1</td><td></td><td>1</td><td></td></tr><tr><td> No</td><td>49</td><td>14.6</td><td>4.9</td><td>5.1 ± 0.3</td><td>0.003</td><td>2.962</td><td>< 0.001</td></tr><tr><td>TACE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>28</td><td>39.9</td><td>4.0</td><td>10.0 ± 1.4</td><td></td><td>1</td><td></td></tr><tr><td> No</td><td>56</td><td>16.6</td><td>8.3</td><td>5.9 ± 0.7</td><td>0.201</td><td>0.893</td><td>0.689</td></tr></table> |
5e076ca34d981d0f34132bc4484f387ea69369dac76013666918eb77f27e2374.png | complex | <table><tr><td rowspan="2">De Qi Characteristics</td><td colspan="2">Acupuncture</td><td></td><td colspan="2">Mock laser</td></tr><tr><td>C 1</td><td>C2</td><td>De Qi Characteristics</td><td>C 1</td><td>C 2</td></tr><tr><td>Dull pain</td><td>.857</td><td></td><td>Heaviness</td><td>.914</td><td></td></tr><tr><td>Sharp pain</td><td>.823</td><td></td><td>Aching</td><td>.887</td><td></td></tr><tr><td>Throbbing</td><td>.770</td><td></td><td>Deep pressure</td><td>.857</td><td></td></tr><tr><td>Cold</td><td>.761</td><td></td><td>Soreness</td><td>.836</td><td></td></tr><tr><td>Tingling</td><td>.728</td><td></td><td>Fullness/ Distension</td><td>.766</td><td></td></tr><tr><td>Warmth</td><td>.697</td><td></td><td>Warmth</td><td>.727</td><td></td></tr><tr><td>Aching</td><td>.575</td><td></td><td>Tingling</td><td>.668</td><td></td></tr><tr><td>Fullness/ Distension</td><td></td><td>−.912</td><td>Sharp pain</td><td>.614</td><td></td></tr><tr><td>Soreness</td><td></td><td>−.899</td><td>Numbness</td><td>.511</td><td></td></tr><tr><td>Deep pressure</td><td></td><td>−.847</td><td>Throbbing</td><td></td><td>.889</td></tr><tr><td>Heaviness</td><td></td><td>−.781</td><td>Cold</td><td></td><td>.847</td></tr><tr><td>Numbness</td><td></td><td>−.664</td><td>Dull pain</td><td></td><td>.598</td></tr></table> |
454ab435c5eb48b6db517e546411c7d2e7a2777def4f47b7496a1958d61148ed.png | complex | <table><tr><td></td><td>Body weight</td><td>BMI</td><td>WC</td><td>VFA</td><td>SFA</td><td>FPG</td><td>2-h PG</td><td>HOMA-IR</td><td>OGIS</td><td>HOMA-β</td><td>II</td></tr><tr><td>Essential AAs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Histidine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Isoleucine</td><td>0.413</td><td>0.305</td><td>0.345</td><td>0.332</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Leucine</td><td>0.488</td><td>0.300</td><td>0.361</td><td>0.413</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Lysine</td><td>0.307</td><td>—</td><td>0.290</td><td>—</td><td>—</td><td>0.236</td><td>—</td><td>—</td><td>−0.257</td><td>—</td><td>—</td></tr><tr><td> Methionine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Phenylalanine</td><td>0.276</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Threonine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Tryptophan</td><td>—</td><td>—</td><td>—</td><td>0.289</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Valine</td><td>0.539</td><td>0.387</td><td>0.482</td><td>0.397</td><td>—</td><td>0.254</td><td>—</td><td>0.219</td><td>−0.297</td><td>—</td><td>—</td></tr><tr><td colspan="2">Nonessential AAs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>—</td></tr><tr><td> Alanine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Arginine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Asparagine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> α-ABA</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Citrulline</td><td>—</td><td>—</td><td>−0.242</td><td>—</td><td>−0.395</td><td>—</td><td>—</td><td>−0.291</td><td>—</td><td>−0.375</td><td>—</td></tr><tr><td> Cystine</td><td>0.276</td><td>—</td><td>0.285</td><td>—</td><td>—</td><td>0.236</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Glutamate</td><td>0.548</td><td>0.443</td><td>0.528</td><td>0.568</td><td>—</td><td>0.439</td><td>0.302</td><td>0.292</td><td>−0.458</td><td>—</td><td>—</td></tr><tr><td> Glutamine</td><td>−0.241</td><td>−0.289</td><td>−0.326</td><td>−0.272</td><td>−0.396</td><td>—</td><td>−0.220</td><td>−0.398</td><td>—</td><td>−0.311</td><td>—</td></tr><tr><td> Glycine</td><td>−0.333</td><td>−0.418</td><td>−0.426</td><td>−0.426</td><td>−0.294</td><td>—</td><td>−0.247</td><td>−0.317</td><td>0.303</td><td>−0.231</td><td>—</td></tr><tr><td> Ornithine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Proline</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Serine</td><td>−0.368</td><td>−0.273</td><td>−0.351</td><td>−0.379</td><td>—</td><td>—</td><td>—</td><td>—</td><td>0.258</td><td>—</td><td>—</td></tr><tr><td> Taurine</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>−0.240</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td> Tyrosine</td><td>0.335</td><td>—</td><td>0.314</td><td>0.252</td><td>—</td><td>0.269</td><td>—</td><td>—</td><td>−0.327</td><td>—</td><td>—</td></tr></table> |
d72c1b5893cc9ac8e62f794206cd23a82af88e4ab4d94da9b3b57614956ca7b6.png | simple | <table><tr><td>Alleles</td><td>Controls <i>n</i> = 426 (%)</td><td>Patients <i>n</i> = 164 (%)</td><td>OR (95% CI)</td><td><i>P</i> value</td></tr><tr><td>rs4938723</td><td></td><td></td><td></td><td></td></tr><tr><td> T</td><td>570 (66.9)</td><td>236 (72.0)</td><td>1.0 (ref)</td><td></td></tr><tr><td> C</td><td>282 (33.1)</td><td>92 (28.0)</td><td>0.79 (0.60–1.04)</td><td>0.10</td></tr><tr><td><i>TP-53</i></td><td></td><td></td><td></td><td></td></tr><tr><td> G</td><td>513 (60.2)</td><td>197 (60.1)</td><td>1.0 (ref)</td><td></td></tr><tr><td> C</td><td>339 (39.8)</td><td>131 (39.9)</td><td>1.01 (0.78–1.31)</td><td>0.96</td></tr></table> |
efcdc30d7130ce3bb7f60252616f794e28515efc34b031b51017b9f8d3665b73.png | simple | <table><tr><td> </td><td>Acyl donor</td><td>Enzyme activity (U/g)</td><td>ees (%)</td></tr><tr><td>1</td><td>Methanol</td><td>41.05 ± 0.65</td><td>24.11 ± 0.06</td></tr><tr><td>2</td><td>Ethanol</td><td>44.16 ± 1.20</td><td>12.12 ± 0.03</td></tr><tr><td>3</td><td>1-Propanol</td><td>33.05 ± 1.57</td><td>16.22 ± 0.08</td></tr><tr><td>4</td><td>1-Butanol</td><td>84.50 ± 1.12</td><td>53.42 ± 0.06</td></tr><tr><td>5</td><td>1-Pentanol</td><td>95.87 ± 0.75</td><td>66.41 ± 0.11</td></tr><tr><td>6</td><td>1-Hexanol</td><td>88.11 ± 0.93</td><td>54.50 ± 0.12</td></tr><tr><td>7</td><td>1-Heptanol</td><td>91.29 ± 0.58</td><td>61.01 ± 0.12</td></tr><tr><td>8</td><td>1-Octanol</td><td>91.43 ± 0.56</td><td>69.42 ± 0.07</td></tr><tr><td>9</td><td>1-Nonanol</td><td>103.9 ± 3.91</td><td>73.91 ± 0.05</td></tr><tr><td>10</td><td>1-Decanol</td><td>106.8 ± 2.56</td><td>83.51 ± 0.03</td></tr><tr><td>11</td><td>Isobutanol</td><td>93.61 ± 2.56</td><td>74.91 ± 0.05</td></tr><tr><td>12</td><td>Isoamylol</td><td>108.95 ± 2.56</td><td>87.51 ± 0.06</td></tr><tr><td>13</td><td>Isooctanol</td><td>115.46 ± 3.12</td><td>95.72 ± 0.04</td></tr><tr><td>14</td><td><i>tert</i>-Butanol</td><td>ND</td><td>ND</td></tr><tr><td>15</td><td><i>tert</i>-Amyl alcohol</td><td>ND</td><td>ND</td></tr><tr><td>16</td><td>1,2-Ethanediol</td><td>ND</td><td>ND</td></tr></table> |
cac31843cad5a2fe7be8452065839951c9c0be3e0a4e919e3a2868c89db2d383.png | simple | <table><tr><td></td><td>LD block<sup>a</sup></td><td>SNP</td><td>Genotype</td><td><i>n</i></td><td>Hazard ratio</td><td>95% confidence interval</td><td><i>P </i>for trend</td></tr><tr><td>IRS1</td><td>1</td><td>rs1801278</td><td>GG</td><td>990</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>GA, AA</td><td>115</td><td>0.82</td><td>0.58, 1.17</td><td></td></tr><tr><td></td><td>1</td><td>rs13306465</td><td>GG</td><td>999</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>GA, AA</td><td>97</td><td>1.44</td><td>1.07, 1.94</td><td></td></tr><tr><td></td><td>1</td><td>rs1801123</td><td>AA</td><td>823</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>AG, GG</td><td>279</td><td>1.37</td><td>1.11, 1.69</td><td></td></tr><tr><td>IGF1R</td><td>11</td><td>rs8038415</td><td>CC</td><td>281</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CT</td><td>536</td><td>1.11</td><td>0.88, 1.41</td><td></td></tr><tr><td></td><td></td><td></td><td>TT</td><td>270</td><td>1.40</td><td>1.07, 1.83</td><td>0.015</td></tr><tr><td></td><td>11</td><td>rs17847201</td><td>GG</td><td>350</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>GA</td><td>581</td><td>0.87</td><td>0.69, 1.10</td><td></td></tr><tr><td></td><td></td><td></td><td>AA</td><td>154</td><td>0.77</td><td>0.56, 1.05</td><td>0.091</td></tr></table> |
6691c902b3216626350bcb5a7eda18bbbc3383bc189d887d9a0e77fb0b76f9de.png | complex | <table><tr><td>Characteristics</td><td>2005-2006</td><td>2006-2007</td><td>2007-2008</td><td>2008-2009</td></tr><tr><td>No. of programs enrolledin ILC</td><td>23</td><td>63</td><td>80</td><td>87</td></tr><tr><td>No. of ILC registrants</td><td>5596</td><td>6920</td><td>6136</td><td>10,327</td></tr><tr><td>Total no. of participantscompleting CKD module</td><td>560</td><td>1322</td><td>1435</td><td>1686</td></tr><tr><td colspan="5">Population included in currentstudy*</td></tr><tr><td>No. of programs</td><td>23</td><td>61</td><td>76</td><td>87</td></tr><tr><td>No. of participants (%)</td><td>509</td><td>1233</td><td>1351</td><td>1609</td></tr><tr><td>PGY-1</td><td>161 (32)</td><td>466 (36)</td><td>503 (37)</td><td>698 (43)</td></tr><tr><td>PGY-2</td><td>176 (34)</td><td>399 (32)</td><td>483 (36)</td><td>482 (30)</td></tr><tr><td>PGY-3</td><td>172 (34)</td><td>388 (32)</td><td>365 (27)</td><td>429 (27)</td></tr><tr><td>Programs affiliated with renalfellowship, n (%)</td><td>11 (48)</td><td>27 (43)</td><td>33 (43)</td><td>38 (44)</td></tr><tr><td colspan="5">Programs by regional ESKDrate, n (%)</td></tr><tr><td>Located in region withhighest ESKD rate</td><td>6 (26)</td><td>26 (43)</td><td>26 (34)</td><td>27 (31)</td></tr><tr><td>Located in region withlowest ESKD rate</td><td>1 (4)</td><td>6 (10)</td><td>4 (5)</td><td>9 (10)</td></tr><tr><td>Mean pre-test score,% (SD)</td><td>45.1 (18.2)</td><td>49.3 (19.3)</td><td>57.0 (20.2)</td><td>55.2 (19.8)</td></tr></table> |
86d7088c8b2a772b40ffd6b809a42d1a315db4265e6960ae79e8618b82b78e72.png | complex | <table><tr><td>Gene (species)</td><td>Sequence 5′→3′</td></tr><tr><td rowspan="2"><i>CCL-2</i> (<i>Homo sapiens</i>) (NM 002982.3)</td><td>Fw: TCA GCC AGA TGC AAT CAA TG</td></tr><tr><td>Rev: ACA CTT GCT GCT GGT GAT TCT</td></tr><tr><td rowspan="2"><i>IL-1<i>β</i></i> (<i>Homo sapiens</i>) (NM 000576.2)</td><td>Fw: AGC CAA TCT TCA TTG CTC AAG T</td></tr><tr><td>Rev: AGT CAT CCT CAT TGC CAC TGT</td></tr><tr><td rowspan="2"><i>IL-6</i> (<i>Homo sapiens</i>) (<i>NM</i> 000600.3)</td><td>Fw: CAG CCC TGA GAA AGG AGA CAT</td></tr><tr><td>Rev: AGC CAT CTT TGG AAG GTT CA</td></tr><tr><td rowspan="2"><i>IFN-<i>γ</i></i> (<i>Homo sapiens</i>) (NM 000619.2)</td><td>Fw: TGG AAA GAG GAG AGT GAC AGA A</td></tr><tr><td>Rev: TTG GAT GCT CTG GTC ATC TTT A</td></tr><tr><td rowspan="2"><i>TNF-</i>α (<i>Homo sapiens</i>) (NM 000594.3)</td><td>Fw: CTC TCT CCC CTG GAA AGG AC</td></tr><tr><td>Rev: ATC ACT CCA AAG TGC AGC AG</td></tr><tr><td rowspan="2"><i>IL- 10</i> (<i>Homo sapiens</i>) (NM 000572.2)</td><td>Fw: TGTCATCGATTTCTTCCCTGT</td></tr><tr><td>Rev: TGC CTT TCT CTT GGA GCT TAT T</td></tr><tr><td rowspan="2"><i>RPL-27</i>(<i>Homo sapiens</i>) (NM 000988.3)</td><td>Fw: CCG AAA TGG GCA AGT TCA T</td></tr><tr><td>Rev: CCA TCA TCA ATG TTC TTC ACG A</td></tr><tr><td rowspan="2"><i>IL-8</i> (<i>Homo sapiens</i>) (NM 000584.3)</td><td>Fw: AGC TCT GTG TGA AGG TGA T</td></tr><tr><td>Rev: TTT GGG GTG GAA AGG TTT G</td></tr><tr><td rowspan="2"><i>ZAG</i> (<i>Homo sapiens</i>) (NM 001185.3)</td><td>Fw: CCA GGA GAA CCA AGA TGG TC</td></tr><tr><td>Rev: CTG CTT CCA ATC CTC CAT TC</td></tr><tr><td rowspan="2"><i>PIF</i> (<i>Homo sapiens</i>) (NM 005268627.1)</td><td>Fw: AGG AAG CAG AGA TCC AGC CT</td></tr><tr><td>Rev: GGC TCC TTT ACC CAC GCT TT</td></tr><tr><td rowspan="2"><i>HPRT1</i>(<i>Homo sapiens</i>) (NM 000194.2)</td><td>Fw: TGG CGT CGT GAT TAG TGA TG</td></tr><tr><td>Rev: CTT GAG CAC ACA GAG GGC TA</td></tr></table> |
a4972e45b92c7f894956914528c12855dbdbd2a43492de3db57512785cf665d7.png | complex | <table><tr><td>Active drugs</td><td>PG</td><td>TMP</td><td>PG</td><td>TMP</td><td>PG</td><td>TMP</td><td colspan="2">Interday RSD%*</td></tr><tr><td>Nominal concentration (<i>μ</i>g/mL)</td><td>80</td><td>0.08</td><td>100</td><td>0.1</td><td>120</td><td>0.12</td><td>PG</td><td>TMP</td></tr><tr><td>Day 1</td><td>99.74</td><td>100.29</td><td>100.65</td><td>98.56</td><td>100.28</td><td>100.72</td><td>0.456</td><td>1.146</td></tr><tr><td>Day 2</td><td>100.38</td><td>98.92</td><td>100.96</td><td>101.24</td><td>99.92</td><td>99.78</td><td>0.521</td><td>1.172</td></tr><tr><td>Day 3</td><td>98.86</td><td>100.79</td><td>99.99</td><td>100.62</td><td>98.99</td><td>99.71</td><td>0.628</td><td>0.579</td></tr><tr><td>Mean</td><td>99.66</td><td>100.34</td><td>100.53</td><td>100.14</td><td>99.73</td><td>100.1</td><td>0.488</td><td>0.139</td></tr><tr><td>Intraday RSD%</td><td>0.76</td><td>0.97</td><td>0.49</td><td>1.4</td><td>0.66</td><td>0.56</td><td> </td><td> </td></tr></table> |
04b54323b6753c7bf2d61f8b602f0c989cdb30378be64288660138efc3e34e6f.png | simple | <table><tr><td>Tool</td><td>URL</td><td>References</td></tr><tr><td>BLAST</td><td>http://blast.ncbi.nlm.nih.gov/Blast.cgi</td><td>(18)</td></tr><tr><td>MAFFT MSA</td><td>http://www.ebi.ac.uk/Tools/msa/mafft/</td><td>(19)</td></tr><tr><td>NetMHCpan</td><td>http://www.cbs.dtu.dk/services/NetMHCpan/</td><td>(20)</td></tr><tr><td>NetMHCIIpan</td><td>http://www.cbs.dtu.dk/services/NetMHCIIpan/</td><td>(21)</td></tr><tr><td>Search tool for HPV antigens</td><td>http://cvc.dfci.harvard.edu/hpv/HTML/search.php</td><td></td></tr><tr><td>Search tool for T cell epitope/HLA ligand</td><td>http://cvc.dfci.harvard.edu/hpv/HTML/searchT.php</td><td></td></tr><tr><td>Blast HPVdb</td><td>http://cvc.dfci.harvard.edu/hpv/HTML/blast.php</td><td></td></tr><tr><td>MSA of HPV sequences</td><td>http://cvc.dfci.harvard.edu/hpv/HTML/alignment.php</td><td></td></tr><tr><td>Sequence variability analysis tool</td><td>http://cvc.dfci.harvard.edu/hpv/HTML/varability.php</td><td>(14)</td></tr><tr><td>T cell epitope/HLA ligand visualization tool</td><td>http://cvc.dfci.harvard.edu/hpv/HTML/viewEpitope.php</td><td></td></tr><tr><td>Classification of the viruses based on cancer risk</td><td>http://cvc.dfci.harvard.edu/hpv/HTML/classification.php</td><td></td></tr><tr><td>HLA binding prediction tool</td><td>Embedded in each antigen entry table</td><td></td></tr><tr><td>T cell epitope/HLA ligand conservation analysis tool</td><td>Embedded in each experimentally validated T cell epitope/HLA entry table; also embedded in each HLA binding prediction result page.</td><td></td></tr></table> |
54db5c24da0807026412150497043b3ba39852519b6b9fb84a58a02bc49ccb0b.png | simple | <table><tr><td>Variable</td><td></td><td>ACRT</td><td>STRT1</td><td>STRT2</td><td>Total</td><td><i>p</i>-value</td></tr><tr><td></td><td></td><td>(45 Gy)</td><td>(60-63 Gy)</td><td>(> 63 Gy)</td><td></td><td></td></tr><tr><td></td><td></td><td>n = 119</td><td>n = 90</td><td>n = 91</td><td></td><td></td></tr><tr><td>Age</td><td>median(range)</td><td>68(41,100)</td><td>67(44,88)</td><td>73(47,95)</td><td>69.5(41,100)</td><td>< 0.001</td></tr><tr><td>Gender</td><td>Female</td><td>48(40.3%)</td><td>43(47.8%)</td><td>50(54.9%)</td><td>141(47.0%)</td><td>0.108</td></tr><tr><td></td><td>Male</td><td>71(59.7%)</td><td>47(52.2%)</td><td>41(45.1%)</td><td>159(53.0%)</td><td></td></tr><tr><td>Smoking Status</td><td>Never</td><td>8(6.8%)</td><td>2(2.2%)</td><td>4(4.4%)</td><td>14(4.7%)</td><td>0.224</td></tr><tr><td></td><td>Quit</td><td>70(59.8%)</td><td>45(50.6%)</td><td>53(58.2%)</td><td>168(56.6%)</td><td></td></tr><tr><td></td><td>Current</td><td>39(33.3%)</td><td>42(47.2%)</td><td>34(37.4%)</td><td>115(38.7%)</td><td></td></tr><tr><td>Karnofsky Performance Status score</td><td>90</td><td>3(2.5%)</td><td>5(5.6%)</td><td>6(6.6%)</td><td>14(4.7%)</td><td>< 0.001</td></tr><tr><td></td><td>80</td><td>35(29.4%)</td><td>58(64.4%)</td><td>40(44.0%)</td><td>133(44.3%)</td><td></td></tr><tr><td></td><td>70</td><td>47(39.5%)</td><td>23(25.6%)</td><td>38(41.8%)</td><td>108(36.0%)</td><td></td></tr><tr><td></td><td>≤ 60</td><td>34(28.6%)</td><td>4(4.4%)</td><td>7(7.7%)</td><td>45(15.0%)</td><td></td></tr><tr><td>Presenting Weight</td><td>No</td><td>56(51.4%)</td><td>67(75.3%)</td><td>61(67.8%)</td><td>184(63.9%)</td><td>0.002</td></tr><tr><td>loss ≥ 5%</td><td>Yes</td><td>53(48.6%)</td><td>22(24.7%)</td><td>29(32.2%)</td><td>104(36.1%)</td><td></td></tr><tr><td>Tumor Stage</td><td>IIIA</td><td>37(31.1%)</td><td>50(55.6%)</td><td>57(62.6%)</td><td>144(48.0%)</td><td>< 0.001</td></tr><tr><td></td><td>IIIB</td><td>82(68.9%)</td><td>40(44.4%)</td><td>34(37.4%)</td><td>156(52.0%)</td><td></td></tr><tr><td>Tumor Histology</td><td>Adenocarcinoma</td><td>37(31.4%)</td><td>31(35.2%)</td><td>41(45.6%)</td><td>109(36.8%)</td><td>0.142</td></tr><tr><td></td><td>Squamous</td><td>42(35.6%)</td><td>34(38.6%)</td><td>32(35.6%)</td><td>108(36.5%)</td><td></td></tr><tr><td></td><td>NSC-NOS</td><td>39(33.1%)</td><td>23(26.1%)</td><td>17(18.9%)</td><td>79(26.6%)</td><td></td></tr><tr><td>Tumor Grade</td><td>Well</td><td>3(2.5%)</td><td>0(0%)</td><td>4(4.4%)</td><td>7(2.3%)</td><td>0.069</td></tr><tr><td></td><td>Moderate</td><td>11(9.2%)</td><td>12(13.3%)</td><td>10(11.0%)</td><td>33(11.0%)</td><td></td></tr><tr><td></td><td>Poor</td><td>37(31.1%)</td><td>42(46.7%)</td><td>29(31.9%)</td><td>108(36.0%)</td><td></td></tr><tr><td></td><td>Unclear</td><td>68(57.1%)</td><td>36(40.0%)</td><td>48(52.7%)</td><td>152(50.7%)</td><td></td></tr><tr><td>Tumor Size (cm)</td><td>median(range)</td><td>5(1,11.5)</td><td>5(1.5,10.5)</td><td>4.2(1,9)</td><td>5(1,11.5)</td><td>0.039</td></tr><tr><td>Induction</td><td>No</td><td>96(80.7%)</td><td>29(32.2%)</td><td>64(70.3%)</td><td>189(63.0%)</td><td>< 0.001</td></tr><tr><td>Chemotherapy</td><td>Yes</td><td>23(19.3%)</td><td>61(67.8%)</td><td>27(29.7%)</td><td>111(37.0%)</td><td></td></tr><tr><td>Adjuvant</td><td>No</td><td>105(88.2%)</td><td>85(94.4%)</td><td>86(94.5%)</td><td>276(92.0%)</td><td>0.15</td></tr><tr><td>Chemotherapy</td><td>Yes</td><td>14(11.8%)</td><td>5(5.6%)</td><td>5(5.5%)</td><td>24(8.0%)</td><td></td></tr></table> |
2119d2e5e6c153510b0db2df3d63d04fd1a03c827511aaaaddf0725cf519b38a.png | simple | <table><tr><td></td><td>FT BMD</td><td>W BMD</td><td>FN BMD</td><td>T BMD</td></tr><tr><td></td><td>β</td><td>β</td><td>β</td><td>β</td></tr><tr><td>Age</td><td>-0.015*</td><td>-0.019*</td><td>-0.001*</td><td>-0.014*</td></tr><tr><td>LDL</td><td>0.238*</td><td>0.151</td><td>0.241*</td><td>0.078</td></tr><tr><td>CA IMT</td><td>-0.467*</td><td>-0.054*</td><td>-0.383*</td><td>-0.489*</td></tr></table> |
f591439670f66b150f7e607a3f10abe624f15b02aafb7ef8dd8951f764f589fc.png | complex | <table><tr><td>Gene</td><td colspan="2">Low n-3 LC-PUFA HL/LL</td><td colspan="2">High n-3 LC-PUFA HH/LH</td></tr><tr><td> </td><td>Microarray</td><td>RT-qPCR</td><td>Microarray</td><td>RT-qPCR</td></tr><tr><td colspan="5"><i>LC-PUFA biosynthesis</i></td></tr><tr><td><i>Δ5fad</i></td><td> </td><td>−1.03</td><td> </td><td>1.35</td></tr><tr><td><i>Δ6fad</i></td><td> </td><td>1.04</td><td> </td><td>−1.32</td></tr><tr><td><i>elovl2</i></td><td>−1.28 to −1.41</td><td>−1.51</td><td>−1.82 to −1.97</td><td>−1.62</td></tr><tr><td colspan="3"><i>Cholesterol biosynthesis</i></td><td> </td><td> </td></tr><tr><td><i>ipi</i></td><td> </td><td>−3.95</td><td> </td><td>1.31</td></tr><tr><td><i>mev</i></td><td> </td><td>−1.40</td><td> </td><td>1.14</td></tr><tr><td><i>7dchr</i></td><td> </td><td>−1.01</td><td> </td><td>1.09</td></tr><tr><td><i>srebp2</i></td><td> </td><td>−2.09</td><td> </td><td>1.29</td></tr><tr><td colspan="4"><i>Lipid transport and lipoprotein metabolism</i></td><td> </td></tr><tr><td><i>lrp1</i></td><td> </td><td>−1.82</td><td> </td><td>−1.08</td></tr><tr><td><i>apoA4a</i></td><td> </td><td>−1.37</td><td> </td><td>−0.95</td></tr><tr><td><i>apoA4b</i></td><td> </td><td>−2.43</td><td> </td><td>−1.80</td></tr><tr><td><i>lpl</i></td><td> </td><td>−1.18</td><td> </td><td>−1.05</td></tr><tr><td colspan="5"><i>Immune response</i></td></tr><tr><td><i>cfh</i></td><td>−1.33 to −1.56</td><td>−1.24</td><td>−1.56 to −1.69</td><td>−1.31</td></tr><tr><td><i>trim25</i></td><td>−5.64</td><td>−2.09</td><td>−4.34</td><td>−2.33</td></tr><tr><td><i>lect2</i></td><td>3.16</td><td>1.23</td><td>4.86</td><td>4.84</td></tr></table> |
89fa92aac62cdb8e119b95449603a4d73fdb84f8e8f340fbf1b1434ca01bfb9c.png | complex | <table><tr><td>Characteristics</td><td>Healthcare worker (%) <i>n</i> = 114</td><td>Other (%)<sup>a</sup><i>n</i> = 41</td></tr><tr><td colspan="3">Country</td></tr><tr><td> Mozambique</td><td>35 (31%)</td><td>36 (88%)</td></tr><tr><td> India</td><td>20 (18%)</td><td>0 (0%)</td></tr><tr><td> Nigeria</td><td>19 (17%)</td><td>5 (12%)</td></tr><tr><td> South Africa</td><td>40 (35%)</td><td>0 (0%)</td></tr><tr><td colspan="3">Facility level</td></tr><tr><td> Community</td><td>40 (35%)</td><td>NA</td></tr><tr><td> Primary health centre</td><td>34 (30%)</td><td>NA</td></tr><tr><td> Hospital</td><td>40 (35%)</td><td>NA</td></tr><tr><td colspan="3">Age (years)</td></tr><tr><td> 15–20</td><td>1 (1%)</td><td>6 (15%)</td></tr><tr><td> 21–30</td><td>36 (32%)</td><td>16 (39%)</td></tr><tr><td> 31–40</td><td>37 (32%)</td><td>15 (37%)</td></tr><tr><td> 41–50</td><td>25 (22%)</td><td>2 (5%)</td></tr><tr><td> 51–60</td><td>13 (11%)</td><td>2 (5%)</td></tr><tr><td> Missing</td><td>2 (2%)</td><td>0 (0)</td></tr><tr><td colspan="3">Gender</td></tr><tr><td> Female</td><td>99 (87%)</td><td>39 (95%)</td></tr><tr><td> Male</td><td>14 (12%)</td><td>2 (5%)</td></tr><tr><td> Missing</td><td>1 (1%)</td><td>0 (0%)</td></tr><tr><td colspan="3">Years of experience</td></tr><tr><td> 0–5</td><td>41 (36%)</td><td>NA</td></tr><tr><td> 6–10</td><td>38 (33%)</td><td>NA</td></tr><tr><td> 11+</td><td>27 (24%)</td><td>NA</td></tr><tr><td> Missing</td><td>8 (1%)</td><td>NA</td></tr></table> |
a0bffc01570781527fa06343baf567a1082cd37d6131a6f217697343980b367f.png | simple | <table><tr><td>Position <sup>1</sup></td><td>NY-3356 Genome</td><td>IC Plasmids</td><td>Amino Acid Change</td><td>Location</td></tr><tr><td>1285</td><td>T</td><td>C</td><td>Silent</td><td>E</td></tr><tr><td>3840</td><td>T</td><td>C</td><td>Silent</td><td>NS2A</td></tr><tr><td>7029<sup>2</sup></td><td>G</td><td>A</td><td>Silent</td><td>NS4B</td></tr><tr><td>7826</td><td>T</td><td>C</td><td>V➔A</td><td>NS5</td></tr><tr><td>8067</td><td>G</td><td>A</td><td>Silent</td><td>NS5</td></tr><tr><td>9123</td><td>C</td><td>T</td><td>Silent</td><td>NS5</td></tr><tr><td>10613</td><td>C</td><td>T</td><td>Silent</td><td>3’ UTR</td></tr><tr><td>10783</td><td>C</td><td>T</td><td>Silent</td><td>3’ UTR</td></tr></table> |
866eff90c6fd93c0fb5f3df67d5000ca8a034e2c338f7c0afb456120c6257aaa.png | complex | <table><tr><td rowspan="2" colspan="2">Observed characteristics</td><td colspan="2">Type of operation</td><td rowspan="2"></td></tr><tr><td>Loop colostomy</td><td>Hartmann’s procedure</td></tr><tr><td colspan="2">Age (X ± SD)</td><td>65.68 ± 14.828</td><td>66.93 ± 11.020</td><td><sup>b</sup>p = 0.678</td></tr><tr><td rowspan="2">Gender</td><td>m</td><td>12 (42.90%)</td><td>23 (50.00%)</td><td rowspan="2"><sup>a</sup>p = 0.551</td></tr><tr><td>f</td><td>16 (57.10%)</td><td>23 (50.00%)</td></tr><tr><td rowspan="4">Randomization groups</td><td>> 60 god, ASA ≥ 3</td><td>12 (16.20%)</td><td>17 (23.00%)</td><td rowspan="4"><sup>a</sup>p = 0.265</td></tr><tr><td>> 60 god, ASA < 3</td><td>4 (5.4%)</td><td>16 (21.60%)</td></tr><tr><td>< 60 god, ASA ≥ 3</td><td>3 (4.10%)</td><td>3 (4.10%)</td></tr><tr><td>< 60 god, ASA < 3</td><td>9 (12.20%)</td><td>10 (13.50%)</td></tr><tr><td rowspan="2">Surgical complications</td><td>Yes</td><td>2 (2.7%)</td><td>2 (2.7%)</td><td rowspan="2"><sup>a</sup>p = 0.579</td></tr><tr><td>No</td><td>25 (34.2%)</td><td>44 (60.3%)</td></tr><tr><td rowspan="2">Nonsurgical complications</td><td>Yes</td><td>3 (4.1%)</td><td>9 (12.3%)</td><td rowspan="2"><sup>a</sup>p = 0.347</td></tr><tr><td>No</td><td>24 (32.9%)</td><td>37 (50.7%)</td></tr></table> |
eccbafa95351c67ad5e06c9d7e1e6ecc70a2db3c860737b3000d2a4d163de70c.png | simple | <table><tr><td>Bioprosthesis type</td><td>Manufacturer</td><td>Valve diameters (mm)</td></tr><tr><td>Trifecta</td><td>St. Jude Medical, Minneapolis, USA</td><td>19 to 29</td></tr><tr><td>Mitroflow</td><td>Sorin Group, Saluggia, Italy</td><td>19 to 29</td></tr><tr><td>Carpentier-Edwards Magna Ease</td><td>Edwards Lifesciences, Irvine, USA</td><td>19 to 29</td></tr></table> |
737f0a45db9c16fd6d806854cf368649b1f16471e75857dba65a0ee53a946bdb.png | complex | <table><tr><td>Clinicopathologic characteristics</td><td>NH (<i>n</i> = 25)</td><td>PTC (<i>n</i> = 25)</td><td>FC (<i>n</i> = 25)</td><td>OvFC (<i>n</i> = 25)</td><td>UDC (<i>n</i> = 22)</td><td><i>P</i></td></tr><tr><td>Age Range (mean ± SD)</td><td>20 – 79 (51 ± 17.3)</td><td>20 – 72 (49 ± 15.1)</td><td>15 – 80 (49 ± 20.2)</td><td>27 – 87 (61 ± 16.2)</td><td>47 – 84 (69 ± 12.01)*</td><td>0.0002*</td></tr><tr><td>Gender</td><td>22 F (88%) 3 M (12%)</td><td>16 F (64%) 9 M (36%)</td><td>19 F (76%) 6 M (24%)</td><td>17 F (68%) 8 M (32%)</td><td>16 F (73%) 6 M (27%)</td><td>NS</td></tr><tr><td>Tumor stage</td><td rowspan="5">N/A</td><td>(<i>n</i> = 25)</td><td>(<i>n</i> = 25)</td><td>(<i>n</i> = 25)</td><td>(<i>n</i> = 22)</td><td></td></tr><tr><td>pT1</td><td>9</td><td>4</td><td>4</td><td>0</td><td>N/A</td></tr><tr><td>pT2</td><td>3</td><td>14</td><td>8</td><td>0</td><td>N/A</td></tr><tr><td>pT3</td><td>13</td><td>7</td><td>11</td><td>0</td><td>N/A</td></tr><tr><td>pT4</td><td>0</td><td>0</td><td>2</td><td>22<sup>#</sup></td><td>N/A</td></tr></table> |
214e09f1569033d489abbc425f15204124963b5b3c9bc8ca959e2584a0a2f114.png | complex | <table><tr><td rowspan="2">Process Modes</td><td colspan="3">Position (cm)</td><td colspan="3">Velocity (cm/s)</td><td colspan="3">Attitude (°)</td></tr><tr><td>North</td><td>East</td><td>Down</td><td>North</td><td>East</td><td>Down</td><td>Roll</td><td>Pitch</td><td>Heading</td></tr><tr><td>IC-PPP</td><td>6.6</td><td>8.9</td><td>6.6</td><td>6.7</td><td>7.2</td><td>8.3</td><td>-</td><td>-</td><td>-</td></tr><tr><td>IC-PPP/INS</td><td>3.2</td><td>4.8</td><td>5.5</td><td>1.0</td><td>1.1</td><td>0.8</td><td>0.021</td><td>0.026</td><td>0.092</td></tr><tr><td>LC-PPP/INS</td><td>4.2</td><td>6.5</td><td>6.1</td><td>1.2</td><td>1.1</td><td>0.9</td><td>0.022</td><td>0.027</td><td>0.095</td></tr></table> |
46d1d8715344274aa0162fb50d48d9194148d8c3345156bbdea8f670771375e0.png | complex | <table><tr><td rowspan="3">Underlying medical condition</td><td colspan="2">All</td><td colspan="2"><5 years</td><td colspan="2">5 - 59 years</td><td colspan="2">60+ years</td><td colspan="2">Pregnant or postpartum</td></tr><tr><td colspan="2"><i>N</i> = 183</td><td colspan="2"><i>n</i> = 29</td><td colspan="2"><i>n</i> = 134</td><td colspan="2"><i>n</i> = 20</td><td colspan="2"><i>n</i> = 27</td></tr><tr><td>Cases</td><td>%</td><td>Cases</td><td>%</td><td>Cases</td><td>%</td><td>Cases</td><td>%</td><td>Cases</td><td>%</td></tr><tr><td>Obesity</td><td>27</td><td>15 %</td><td>0</td><td>0 %</td><td>23</td><td>17 %</td><td>4</td><td>21 %</td><td>2</td><td>7 %</td></tr><tr><td>Diabetes Mellitus</td><td>23</td><td>13 %</td><td>0</td><td>0 %</td><td>16</td><td>12 %</td><td>7</td><td>37 %</td><td>2</td><td>7 %</td></tr><tr><td>Asthma</td><td>20</td><td>11 %</td><td>2</td><td>7 %</td><td>15</td><td>11 %</td><td>3</td><td>16 %</td><td>5</td><td>18 %</td></tr><tr><td>Other chronic metabolic disease</td><td>15</td><td>8 %</td><td>1</td><td>3 %</td><td>9</td><td>7 %</td><td>5</td><td>26 %</td><td>0</td><td>0 %</td></tr><tr><td>Immunosuppression</td><td>15</td><td>8 %</td><td>2</td><td>7 %</td><td>10</td><td>7 %</td><td>3</td><td>16 %</td><td>1</td><td>4 %</td></tr><tr><td>Chronic lung disease</td><td>10</td><td>5 %</td><td>0</td><td>0 %</td><td>8</td><td>6 %</td><td>2</td><td>11 %</td><td>2</td><td>7 %</td></tr><tr><td>Chronic seizures</td><td>11</td><td>6 %</td><td>3</td><td>10 %</td><td>8</td><td>6 %</td><td>0</td><td>0 %</td><td>0</td><td>0 %</td></tr><tr><td>Chronic cardiac disease</td><td>7</td><td>4 %</td><td>1</td><td>3 %</td><td>5</td><td>4 %</td><td>1</td><td>5 %</td><td>3</td><td>11 %</td></tr><tr><td>Cerebral palsy</td><td>7</td><td>4 %</td><td>1</td><td>3 %</td><td>6</td><td>4 %</td><td>0</td><td>0 %</td><td>0</td><td>0 %</td></tr><tr><td>At least one chronic condition</td><td>112</td><td>61 %</td><td>11</td><td>38 %</td><td>82</td><td>61 %</td><td>19</td><td>100 %</td><td>14</td><td>50 %</td></tr></table> |
531ff1645f61cbfb5046faff5a4c184251049dd7cb75a724c782c2b3c7c3d88c.png | simple | <table><tr><td> </td><td>All gabor</td><td>Papillary gabor</td><td>Reticular gabor</td><td>All FFT</td><td>Papillary FFT</td><td>Reticular FFT</td></tr><tr><td>95% CI</td><td>−0.999 to −0.209</td><td>−0.999 to 0.284</td><td>−0.999 to −0.276</td><td>−0.370 to 0.999</td><td>−0.574 to 0.997</td><td>−0.171 to 0.999</td></tr><tr><td>P value</td><td>0.0128</td><td>0.0206</td><td>0.0111</td><td>0.0413</td><td>0.0683</td><td>0.0272</td></tr><tr><td>R<sup>2</sup></td><td>0.950</td><td>0.920</td><td>0.956</td><td>0.842</td><td>0.7454</td><td>0.8941</td></tr></table> |
9db7f4ffd6e8ef1e9691d054bc0e960663554f17379cce8843043f3bf6a2ed51.png | complex | <table><tr><td rowspan="2">Follow-up</td><td>Targeted group</td><td>Nontargeted group</td><td>Medium alone</td></tr><tr><td>(<i>n</i> = 8)</td><td>(<i>n</i> = 8)</td><td>(<i>n</i> = 8)</td></tr><tr><td>0 d</td><td>0.140 ± 0.024</td><td>0.156 ± 0.029</td><td>0.134 ± 0.030</td></tr><tr><td>1 d</td><td>0.463 ± 0.032</td><td>0.160 ± 0.031</td><td>0.155 ± 0.032</td></tr><tr><td>3 d</td><td>0.328 ± 0.057</td><td>0.145 ± 0.029</td><td>0.122 ± 0.025</td></tr><tr><td>7 d</td><td>0.237 ± 0.025</td><td>0.109 ± 0.031</td><td>0.140 ± 0.024</td></tr><tr><td>10 d</td><td>0.182 ± 0.028</td><td>0.118 ± 0.041</td><td>0.126 ± 0.021</td></tr></table> |
ba3a9ad9fa5b5b087a3fb70058a407c86d11e110b8255dca257111b214f4ed34.png | simple | <table><tr><td> </td><td>Korea</td><td>Japan</td></tr><tr><td>Expenditures on health by type of funding (%)</td><td> </td><td> </td></tr><tr><td>GG/SS/POP/PI</td><td>11/46/37/6</td><td>9/73/15/2</td></tr><tr><td>Share of hospital inpatient expenditures for MSD (%)</td><td>9</td><td>6</td></tr><tr><td>Health care system</td><td> </td><td> </td></tr><tr><td>Out-of-pocket healthcare expenditures as a share of total household consumption (%)</td><td>4.6</td><td>2.2</td></tr><tr><td>Sickness leave</td><td>No</td><td>66.7% of average daily basic wage up to 18 months</td></tr><tr><td>Share of WMSD in workers’ compensation (%)</td><td> </td><td> </td></tr><tr><td>WMSD/total compensated diseases</td><td>71.5</td><td>66.6</td></tr><tr><td>WMSD/total compensated injury and diseases</td><td>5.8</td><td>4.3</td></tr></table> |
db537b83df4bba2095fdf9c692c169300d80fd13220af271fac463194fdb01a1.png | simple | <table><tr><td>Parameter</td><td>Cirrhosis</td><td>Controls</td></tr><tr><td>Bilirubin (total, mg/dL)</td><td>1.44 ± 0.95</td><td>0.89 ± 0.24</td></tr><tr><td>Albumin (gm/dL)</td><td>4.0 ± 0.5</td><td>3.7 ± 0.9</td></tr><tr><td>PT (secs)</td><td>14.4 ± 1.8</td><td>11.4 ± 0.8</td></tr><tr><td>Ascites</td><td>2/26</td><td>0/13</td></tr><tr><td>Enceplalopathy</td><td>0/26</td><td>0/13</td></tr></table> |
4622451f4cbf2e91926520100a8ba78aa80ffdb11890e8927bad8317fb5bd8b1.png | simple | <table><tr><td>Symbol</td><td>Chr</td><td>UCSC annotated features</td><td>CpG island</td><td>Δ β-value</td><td>Bootstrap 95% CI</td></tr><tr><td>OBFC2B</td><td>12</td><td>Promoter associated</td><td>Shore</td><td>0.386</td><td>(0.227, 0.551)</td></tr><tr><td>GPR75; LOC100302652</td><td>2</td><td>5′UTR; 1st Exon; Enhancer</td><td>Island</td><td>0.349</td><td>(0.184, 0.515)</td></tr><tr><td>AIRE</td><td>21</td><td>Within 100 bp of TSS</td><td>Island</td><td>0.267</td><td>(0.094, 0.444)</td></tr><tr><td>MIMT1; PEG3;ZIM2</td><td>19</td><td>Within 500 bp of TSS; 5′UTR; 5′UTR</td><td>Island</td><td>0.207</td><td>(0.088, 0.332)</td></tr><tr><td>CIRBP; C19orf24</td><td>19</td><td>Body; Within 1000 bp of TSS</td><td>Island</td><td>0.176</td><td>(0.097, 0.256)</td></tr><tr><td>SMG6; SRR</td><td>17</td><td>Within 500 bp of TSS; 5′UTR</td><td>Shore</td><td>0.125</td><td>(0.039, 0.214)</td></tr><tr><td>GPR12</td><td>13</td><td>5′UTR</td><td>Island</td><td>-0.095</td><td>(-0.161, -0.030)</td></tr></table> |
458709d6c2b706d70b4a09ca601e23a7547e7c611f08452461f25d6b94ec6385.png | simple | <table><tr><td>Rab</td><td>Determination on WPBs</td><td>Method</td><td>siRNA effect on VWF release</td><td>Comment</td><td>Reference</td></tr><tr><td>Rab27a</td><td>Endogenous expression and overexpression</td><td>Western blot, RT-PCR, and IF</td><td>Increase or decrease</td><td>–</td><td>26,34,47,50</td></tr><tr><td>Rab27b</td><td>Overexpression</td><td>RT-PCR</td><td>Decrease</td><td>Level of expression very low</td><td>47</td></tr><tr><td>Rab3A</td><td>Overexpression</td><td>RT-PCR</td><td>Decrease</td><td>–</td><td>47</td></tr><tr><td>Rab3B</td><td>Endogenous expression and overexpression</td><td>Western blot, RT-PCR, and IF</td><td>No effect</td><td>–</td><td>47,50</td></tr><tr><td>Rab3D</td><td>Endogenous expression and overexpression</td><td>Western blot, RT-PCR, and IF</td><td>Decrease or no effect</td><td>Endogenous Rab3D weakly detectable in 5% of cells</td><td>47,50,52</td></tr><tr><td>Rab15</td><td>Overexpression</td><td>RT-PCR</td><td>Decrease</td><td>–</td><td>47</td></tr><tr><td>Rab33a</td><td>Overexpression</td><td>RT-PCR</td><td>No effect</td><td>–</td><td>47</td></tr><tr><td>Rab37</td><td>Overexpression</td><td>RT-PCR</td><td>No effect</td><td>Low expression (cycle time 39.74)</td><td>47</td></tr></table> |
b660d08756e25702aac2c80719509fd02e733568eba8dfe22ee53806ddc0a93f.png | complex | <table><tr><td></td><td>Region</td><td>Number</td><td>Mean ± SD</td><td>Min–max</td><td>Median</td><td>Lower quartile</td><td>Upper quartile</td></tr><tr><td rowspan="4">NP (ng g<sup>−1</sup> dw)</td><td>Bornholm Deep</td><td>13</td><td>14.04 ± 21.50</td><td>ND–71.92</td><td>3.21</td><td>1.64</td><td>22.88</td></tr><tr><td>S-W Gotland Deep</td><td>13</td><td>68.67 ± 95.50</td><td>0.43–239.88</td><td>8.09</td><td>1.51</td><td>170.08</td></tr><tr><td>Gdansk Deep</td><td>13</td><td>27.39 ± 30.60</td><td>0.71–74.59</td><td>5.60</td><td>2.07</td><td>57.36</td></tr><tr><td>Slope of the Gdansk Deep</td><td>13</td><td>2.47 ± 4.53</td><td>ND–15.80</td><td>0.59</td><td>0</td><td>2.96</td></tr><tr><td rowspan="4">OP (ng g<sup>−1</sup> dw)</td><td>Bornholm Deep</td><td>13</td><td>3.71 ± 2.04</td><td>ND–7.99</td><td>3.72</td><td>3.18</td><td>5.00</td></tr><tr><td>S-W Gotland Deep</td><td>13</td><td>5.96 ± 3.77</td><td>2.08–13.01</td><td>3.99</td><td>3.38</td><td>7.83</td></tr><tr><td>Gdansk Deep</td><td>13</td><td>1.72 ± 1.52</td><td>0.25–5.61</td><td>1.39</td><td>0.83</td><td>1.88</td></tr><tr><td>Slope of the Gdansk Deep</td><td>13</td><td>1.46 ± 2.55</td><td>ND–9.68</td><td>0.58</td><td>0.40</td><td>1.58</td></tr></table> |
18bbbce7e152f7915bc13f0a51f853536b2b08e4cdd3032cc581b71cbcfc6a1e.png | complex | <table><tr><td></td><td>Odds ratio</td><td colspan="2">95 % C.I. for odds ratio</td><td><i>P</i> value</td></tr><tr><td></td><td></td><td>Lower</td><td>Upper</td><td></td></tr><tr><td>External environment</td><td></td><td></td><td></td><td></td></tr><tr><td>Area of residence</td><td></td><td></td><td></td><td></td></tr><tr><td>Rural</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Urban</td><td>1.364</td><td>1.081</td><td>1.721</td><td>0.009</td></tr><tr><td>Education</td><td></td><td></td><td></td><td></td></tr><tr><td>Non</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Primary</td><td>1.666</td><td>1.297</td><td>2.141</td><td>0.001</td></tr><tr><td>Secondary +</td><td>1.929</td><td>1.380</td><td>2.697</td><td>0.001</td></tr><tr><td>Adult education</td><td>1.191</td><td>.688</td><td>2.063</td><td>0.533</td></tr><tr><td>Wealth index</td><td></td><td></td><td></td><td></td></tr><tr><td>Wealth index(score)</td><td>2.293</td><td>1.988</td><td>2.644</td><td>0.001</td></tr><tr><td>Parity</td><td></td><td></td><td></td><td></td></tr><tr><td>Parity >2</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Parity 1-2</td><td>2.222</td><td>1.786</td><td>2.765</td><td>0.001</td></tr><tr><td>Enabling factors</td><td></td><td></td><td></td><td></td></tr><tr><td>Ante natal care</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>3.342</td><td>2.306</td><td>4.844</td><td>0.001</td></tr><tr><td>Need factors</td><td></td><td></td><td></td><td></td></tr><tr><td>Complications during pregnancy</td><td></td><td></td><td></td><td></td></tr><tr><td>No/Non-serious complication</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Serious complication</td><td>1.606</td><td>1.319</td><td>1.957</td><td>0.001</td></tr></table> |
e93e7819a24b94a3d7771d645966b6773a2e419fb8815a57b6459f1eada76e10.png | simple | <table><tr><td>Gene</td><td>Sequence</td></tr><tr><td>GK</td><td>forward 5′-TTGAGACCCGTTTCGTGTCA – 3′</td></tr><tr><td></td><td>reverse 5′-AGGGTCGAAGCCCCAGAGT -3′</td></tr><tr><td>L-PK</td><td>forward 5′-TGATGATTGGACGCTGCAA – 3′</td></tr><tr><td></td><td>reverse 5′-GAGTTGGTCGAGCCTTAGTGATC – 3′</td></tr><tr><td>HK2</td><td>forward 5′-AACCGAACAAGCTGGTGTAC-3′</td></tr><tr><td></td><td>reverse 5′-TGCACACATCTATAGGTGGC-3′</td></tr><tr><td>ACC</td><td>forward 5′-CAACGCCTTCACACCACCTT -3′</td></tr><tr><td></td><td>reverse 5′-AGCCCATTACTTCATCAAAGATCCT -3′</td></tr><tr><td>FAS</td><td>forward 5′-TGCTCCCAGCTGCAG -3′</td></tr><tr><td></td><td>reverse 5′-GCCCGGTAGCTCTGGGTGTA -3′</td></tr><tr><td>ACOX1</td><td>forward 5′-AAGAAATCCCCACTGAACAAAACA -3′</td></tr><tr><td></td><td>reverse 5′-CCCAGGGAAACTTCAAAGCTT -3′</td></tr><tr><td>CPT1a</td><td>forward 5′-ATATCAAGGACAGCAGGCACAT -3′</td></tr><tr><td></td><td>reverse 5′-CTCAGCAGCCTCCCATGCT -3′</td></tr><tr><td>CPT1 b</td><td>forward 5′-CAGCCATGCCACCAAGATC -3′</td></tr><tr><td></td><td>reverse 5′-CTTGGGCAGTGATGTTTGGA -3′</td></tr><tr><td>CD36</td><td>forward 5′-CAGCCTCCTTTCCACCTTTTG-3′</td></tr><tr><td></td><td>reverse 5′-AAGGCGTTGGCTGGAAGAA-3′</td></tr><tr><td>PGC1α</td><td>forward 5′-ATACCGCAAAGAGCACGAGAAG-3′</td></tr><tr><td></td><td>reverse 5′-CTCAAGAGCAGCGAAAGCGTCACAG-3′</td></tr><tr><td>PPARα</td><td>forward 5′-GGGATGAAGAGGGCTGAGC-3′</td></tr><tr><td></td><td>reverse 5′-TGATTAACATTGGGCCGGTT-3′</td></tr><tr><td>BCAT2</td><td>forward 5′-GGCGGACCCTTCATTCGT-3′</td></tr><tr><td></td><td>reverse 5′-TTCCCCCCCAACTTGCA-3′</td></tr><tr><td>BCKDHα</td><td>forward 5′-CCAGGGTTGGTGGGATGAG-3′</td></tr><tr><td></td><td>reverse 5′-GGCTTCCATGACCTTCTTTCG-3′</td></tr><tr><td>UBE2B</td><td>forward 5′-AACGCAGTTATATTTGGACCAGAAG-3′</td></tr><tr><td></td><td>reverse 5′-ACGGTTGGTGGTTTATTTGGAT-3′</td></tr><tr><td>CAD</td><td>forward 5′-CGCAGTGTTTCACAGTCGTCTT-3′</td></tr><tr><td></td><td>reverse 5′-TGGACTTGTCACTGTTGTACTTATGG-3′</td></tr><tr><td>CCK</td><td>forward 5′-CAGGTCCGCAAAGCTCCTT3′</td></tr><tr><td></td><td>reverse 5′-TCCAGGCTCTGCAGGTTCTT-3′</td></tr><tr><td>PYY</td><td>forward 5′-CGGCAGCGGTATGGAAAA-3′</td></tr><tr><td></td><td>reverse 5′-TGTGAAGAGCAGTTTGGAGAACA-3′</td></tr><tr><td>GLP-1</td><td>forward 5′-CTCCCGCCGTGCTCAA-3′</td></tr><tr><td></td><td>reverse 5′-TTGTTCCGGTTCCTCTTGGT-3′</td></tr><tr><td>GIP</td><td>forward 5′-CTGCTGGTGCTCCTGTTCCT-3′</td></tr><tr><td></td><td>reverse 5′-CATGGGATCGGAACTCAACCT-3′</td></tr></table> |
ed4fefecc487fea5c31dafbdd58df8e30f10cf1dad2eeb6bd7d34e8599791eed.png | simple | <table><tr><td>Time (weeks)</td><td>NC group</td><td>DN group</td><td>BH group</td></tr><tr><td>8</td><td>3.158 ± 0.505</td><td>7.059 ± 0.586<sup>*</sup></td><td>5.894 ± 0.418<sup>*#</sup></td></tr><tr><td>12</td><td>3.273 ± 0.520</td><td>8.024 ± 0.693<sup>*</sup></td><td>6.103 ± 0.521<sup>*#</sup></td></tr><tr><td>16</td><td>3.281 ± 0.299</td><td>9.211 ± 0.453<sup>*</sup></td><td>6.723 ± 0.283<sup>*#</sup></td></tr></table> |
c49b509c96390bc9c91b6352ddf1b0c0fbb64fcfb5405e0495e07111d9e3d192.png | simple | <table><tr><td>Discipline</td><td>Number</td></tr><tr><td>Medical</td><td>11,323</td></tr><tr><td>Nurses and midwives</td><td>40,926</td></tr><tr><td>Dentists</td><td>3,176</td></tr><tr><td>Pharmacists</td><td>1,100</td></tr><tr><td>Other HCW</td><td>16,640</td></tr><tr><td>Administrative staff</td><td>34,533</td></tr><tr><td>Total</td><td>107,698</td></tr></table> |
bf1528b26a85fd8f77da6f21857c0e90645512cf098a419fbf0013cd98b9d9b5.png | simple | <table><tr><td></td><td></td><td>Chi-square test of model fit</td><td>DF</td><td>Model comparison (Δ Chi-square)</td><td>Δ DF</td><td>RMSEA</td><td>CFI</td><td>TLI</td><td>SRMR</td></tr><tr><td>A</td><td>(M ->DV)</td><td>728.378<sup>***</sup></td><td>145</td><td></td><td></td><td>0.044</td><td>0.931</td><td>0.920</td><td>0.047</td></tr><tr><td>B</td><td>(IV-> DV)</td><td>829.245<sup>***</sup></td><td>144</td><td>−100.867<sup>***</sup> (A–B)</td><td>1</td><td>0.048</td><td>0.919</td><td>0.905</td><td>0.053</td></tr><tr><td>C</td><td>(IV -> M -> DV)</td><td>718.757<sup>***</sup></td><td>143</td><td>110.488<sup>***</sup> (B–C)</td><td>1</td><td>0.044</td><td>0.932</td><td>0.920</td><td>0.045</td></tr><tr><td></td><td></td><td></td><td></td><td>9.621<sup>**</sup> (A–C)</td><td>2</td><td></td><td></td><td></td><td></td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.